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Abbreviations and glossary of terms 
Abbreviations 
APPG PDD All Party Parliamentary Group on Prescribed Drug Dependence 
 
BMA British Medical Association 
 
CPRD / GPRD Originally called the General Practice Research Database (GPRD), the 
Clinical Practice Research Datalink (CPRD) collates patient data from a large sample of 
primary care practices 
 
OPM Opioid pain medicines 
 
PMR Prescribed Medicines Review, shorthand for PHE’s review of the evidence for 
dependence on, and withdrawal from, some prescribed medicines 
 
Glossary of terms 
Terms used in definition text that are further defined themselves are shown in italics. 
 
Addiction Dependence plus a compulsive preoccupation to seek and take a substance 
despite consequences 
 
Dependence An adaptation to repeated exposure to some drugs and medicines 
usually characterised by tolerance and withdrawal, though tolerance may not occur with 
some. Dependence is an inevitable (and often acceptable) consequence of long-term 
use of some medicines and is distinguished here from addiction 
 
Discontinuation (syndrome) This term was used in the early stages of the review as it 
was the only term recognised by some stakeholders in relation to the effects 
experienced by some patients when coming off antidepressants. However, it is a 
contentious term and has only been kept in the search terms and other processes of 
the review to ensure that a full range of appropriate evidence is captured. The term is 
no longer used in the review's outputs 
 
Tolerance Neuroadaptation arising from repeatedly taking some drugs and medicines, 
in which higher doses are required to achieve a desired effect 
 
Withdrawal Physiological reactions when a drug or medicine that has been taken 
repeatedly is removed
Prescribed medicines: an evidence review 
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What this report means for patients 
More people are taking prescribed medicines for longer 
Some prescription medicines can be addictive and could cause problems for people 
taking them or coming off them, especially if someone has been taking them for a long 
time. These medicines include benzodiazepines and z-drugs, gabapentin and 
pregabalin, and opioid pain medicines. Antidepressants are not addictive but some 
people have problems coming off them. 
 
The government asked Public Health England to look at the evidence about this 
problem. We found that, since at least 10 years ago, more people are being prescribed 
more of these medicines and often for longer.  
 
The prescribing of some of these medicines (like benzodiazepines and opioids) has 
fallen recently but others (such as gabapentin, pregabalin and antidepressants) are 
being prescribed more and for longer. This means more people are at risk of becoming 
addicted to them or having problems when they stop using them. It also costs the NHS 
a lot of money, some of which is wasted because the medicines do not work for 
everyone all the time, especially if they are used for too long. 
 
Do not stop taking a prescribed medicine on your own 
The medicines we looked at help to make millions of people every year feel better and 
recover from their illness. Doctors can prescribe them because there is good evidence 
that they work, but they do have some risks. If you are a patient taking one of these 
medicines as prescribed by your doctor (or other prescriber), but you are worried by 
anything in this report, you should not stop taking them on your own. Instead, make an 
appointment to see your doctor and talk through your worries. 
 
We do not want to put anyone off safely using medicines that could help them. Stopping 
or limiting the use of medicines could also cause harm, including increasing the risk of 
suicide or making people try to get medicines or illegal alternatives from less safe 
sources, such as illegal websites or drug dealers. 
 
What your doctor should do 
Because of this report – and work being done by lots of others – doctors and other 
healthcare professionals should: 
 
• consider all the treatments that might work for you, including those that don’t involve 
(or are in addition to) medicines, like talking therapies or exercise 
Prescribed medicines: an evidence review 
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• tell you about the benefits and risks of medicines 
• regularly review whether a medicine is helping you or not 
• change the treatment if it’s not helping you 
 
They might offer some patients the chance to gradually come off a medicine they have 
been taking for a long time.  
 
If you need to start taking a medicine, or need to continue taking one, your doctor will 
always try to do what is in your best interests. 
 
If you believe what your doctor is doing is not in your best interests you should talk to 
them first. You have the right to make a complaint and the right to ask for a second 
opinion. If you want support to make a complaint you can contact your local NHS 
Complaints Advocacy Service. Your local Healthwatch can also give you more 
information.   
 
We also recommend that there should be improvements in the information, advice and 
support available to patients from doctors and specialist services. If you have problems 
coming off a medicine, tell your doctor and they should offer you more support or put 
you in touch with another service that can help. 
 




In 2017, the minister for public health and primary care commissioned Public Health 
England (PHE) to identify the scale, distribution and causes of prescription drug 
dependence, and what might be done to address it. 
 
The review covered adults (aged 18 and over) and 5 classes of medicines:  
 
• benzodiazepines (mostly prescribed for anxiety) 
• z-drugs (sleeping tablets with effects similar to benzodiazepines) 
• gabapentin and pregabalin (together called gabapentinoids and used to treat 
epilepsy, neuropathic pain and, in the case of pregabalin, anxiety) 
• opioids for chronic non-cancer pain 
• antidepressants 
 
The National Institute for Health and Care Excellence (NICE) first mapped out all the 
medicines prescribable in England in these classes so it was clear which were to be 
included. 
 
This was a mixed-methods public health evidence review, including: 
 
1. An analysis by PHE of all NHS community prescriptions in England reported to 
the NHS Business Services Authority during the period 2015 to 2018 (patient-
linked data only available since 2015), supplemented by some longer-term 
prescription data that could better indicate trends, and data on medicines 
supplied in other settings. 
 
2. An independently commissioned rapid evidence assessment (REA) of articles on 
prescription medicine-associated harms, dependence, withdrawal, risk factors 
and service models published between 2008 and 2018, and of documents 
submitted in an open public call-for-evidence which summarises patients’ 
experiences of taking these medicines and of treatment services. 
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Findings from the analysis of prescription data  
Prevalence 
PHE’s analysis shows that, in 2017 to 2018, 11.5 million adults in England (26% of the 
adult population) received, and had dispensed, one or more prescriptions for any of the 
medicines within the scope of the review.i The totals for each medicine were: 
 
• antidepressants 7.3 million people (17% of the adult population) 
• opioid pain medicines 5.6 million (13%) 
• gabapentinoids 1.5 million (3%) 
• benzodiazepines 1.4 million (3%) 
• z-drugs 1.0 million (2%) 
 
There are large variations in the standardised rates of prescribing across clinical 
commissioning groups (CCGs). 
 
Trends and demographics 
Between 2015 to 2016 and 2017 to 2018 the rate of prescribing for antidepressants 
increased from 15.8% of the adult population to 16.6% and for gabapentinoids from 
2.9% to 3.3%. There was a small decrease in prescribing rates for the other 3 medicine 
classes. 
 
Rates of prescribing were higher for women (1.5 times those of men), and the rates 
generally increased with age. 
 
After a long increasing trend, the annual number of prescriptions for opioid pain 
medicines has slightly decreased since 2016. 
 
There is a continuing longer-term fall in prescription numbers for benzodiazepines. A 
longer-term increase in annual prescription numbers for z-drugs started to reverse in 
2014. 
 
Associations with deprivation 
Prescribing rates for opioid pain medicines and gabapentinoids had a strong association 
with deprivation, being higher in areas of greater deprivation. Antidepressant prescribing 
                                            
 
 
i Other than opioid prescriptions for cancer pain, which were excluded as far as possible through a match to the 
National Cancer Registration Dataset, it was not possible to identify the conditions for which these medicines were 
prescribed, as conditions are not recorded in prescription data. 
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had a weaker association with deprivation. For benzodiazepines and z-drugs, 
prescribing rates slightly decreased with higher deprivation. For all medicine classes the 
proportion of patients who had at least a year of prescriptions increased with higher 
deprivation. 
 
Time receiving prescriptions 
Most patients who started a prescription in June 2015 were estimated to have received 
a prescription for 3 months or less. This ranged from 51% for antidepressants to 82% 
for benzodiazepines. 
 
The proportion estimated to have received a prescription continuously from June 2015 
for at least 12 months varied from 5% (benzodiazepines) to almost 20% 
(gabapentinoids). These proportions were similar, at 4% and 19% respectively, for 
those starting a prescription in June 2017, the latest date at which 12-month duration 
could be estimated prospectively. This suggests that most people who start 
prescriptions receive them for a short time, but each month there is a group of patients 
who continue to receive a prescription for longer. 
 
Looking retrospectively at people receiving a prescription in March 2018, around half of 
patients in each medicine class were estimated to have been receiving a prescription 
continuously for at least 12 months at that point. This proportion is much higher than for 
those starting a prescription in June 2015 as it reflects an accumulation of people who 
have long-term prescriptions, some of whom started prescriptions more recently, but 
many of whom were already receiving prescriptions by April 2015. 
 
The number of patients who received a prescription continuously between April 2015 
(and perhaps earlier) and March 2018 was as follows:  
 
• antidepressants 930,000 people 
• opioid pain medicines 540,000 
• gabapentinoids 160,000 
• benzodiazepines 120,000 
• z-drugs 100,000 
 
Findings from the rapid evidence assessment 
The REA identified 75 articles which included: 
 
• 30 on harms 
• 26 on interventions 
• 17 on risk factors 
• 2 on patients’ experiences 
Prescribed medicines: an evidence review 
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From the open call-for-evidence, the researchers included 10 more reports on patients’ 
experiences and 4 reports on current practice. 
 
Dependence, withdrawal and interventions 
Benzodiazepines, z-drugs, opioid pain medicines and gabapentinoids are associated 
with a risk of dependence and withdrawal. 
 
Antidepressants are associated with withdrawal. Seventeen placebo-controlled trials 
(with 6,729 participants) show that withdrawal symptoms, such as insomnia, 
depression, suicidal ideation and physical symptoms, follow when patients stop taking 
medication. The evidence here was mostly very-low to moderate-quality. Only 1 trial 
was high quality. 
 
Interventions for treating dependence and managing withdrawal varied widely, and 
meta-analysis, or combining data from the studies, was not feasible. The evidence here 
came from 26 trials and 2 non-randomised studies: 12 on opioids, 8 benzodiazepines, 3 
antidepressants, 1 z-drugs and 4 on several drugs. 
 
Patients’ experiences 
Some patients reported harmful effects and withdrawal symptoms on stopping 
benzodiazepines, z-drugs, opioids and antidepressants which affected their well-being, 
personal, social and occupational functioning. These effects and symptoms could last 
many months. 
 
Higher initial opioid doses and prior mental health problems were associated with long-
term use of opioids and opioid dependence, respectively. Prescribing opioid pain 
medicines for longer than 90 days was associated with opioid overdose and 
dependence. 
 
Low income and use of shorter-acting benzodiazepines are associated with long-term 
benzodiazepine use. 
 
Patients experienced barriers to accessing and engaging in treatment services. They 
felt there was a lack of information on the risks of medication and that doctors did not 
acknowledge or recognise withdrawal symptoms. 
 
Patients described not being offered any non-medicinal treatment options, their 
treatment not being reviewed sufficiently and a lack of access to effective management 
and NHS support services.  
 




The evidence submitted was not enough for conclusions on the effectiveness and cost-
effectiveness of service models. 
 
Common features of service models submitted were: 
 
• the involvement of GPs and other primary care services 
• helpline and telephone support 
• counselling and support groups 
 
Conclusions 
In England in the year 2017 to 2018, one in 4 adults in England were prescribed 
benzodiazepines, z-drugs, gabapentinoids, opioids for chronic non-cancer pain, or 
antidepressants. Prescriptions for antidepressants and gabapentinoids are increasing, 
but prescriptions for opioid pain medicines are decreasing, after rising for many years. 
Prescriptions for benzodiazepines continue to fall, and those for z-drugs have more 
recently started to fall.  
 
There is a higher rate of prescribing to women and older adults, and there are large 
variations in standardised rates of prescribing at the level of CCGs. The rate of 
prescribing and the time receiving a prescription increase with deprivation.  
 
Longer-term prescribing is widespread. Aside from antidepressants, the medications 
reviewed are all licensed and indicated for (usually) short-term treatment of acute 
conditions. Clinical guidelines specify that benzodiazepines should not usually be 
prescribed for longer than 2 to 4 weeks. Long-term prescribing of opioids for chronic, 
non-cancer pain is not effective for most patients. And some patients need long-term 
prescribing of antidepressants to maintain benefit and prevent relapse.  
 
Effective, personalised care should include shared decision making with patients and 
regular reviews of whether treatment is working. Patients who want to stop using a 
medicine must be able to access appropriate medical advice and treatment, and must 
never be stigmatised.  
 
Inappropriate limiting of medicines may increase harm, including the risk of suicide, and 
lead some people to seek medicines from illicit or less-regulated sources, such as 
online pharmacies. There needs to be increased public and clinical awareness of other 
interventions, such as cognitive behavioural therapy.  
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There have been very few high-quality research studies on medicine dependence and 
withdrawal, and their prevention and treatment, in the past 10 years.  
 
Recommendations 
PHE’s recommendations fall into 5 broad categories which are:  
 
1. Increasing the availability and use of data on the prescribing of medicines that can 
cause dependence or withdrawal to support greater transparency and accountability 
and help ensure practice is consistent and in line with guidance. 
2. Enhancing clinical guidance and the likelihood it will be followed. 
3. Improving information for patients and carers on prescribed medicines and other 
treatments, and increasing informed choice and shared decision making between 
clinicians and patients. 
4. Improving the support available from the healthcare system for patients experiencing 
dependence on, or withdrawal from, prescribed medicines. 
5. Further research on the prevention and treatment of dependence on, and withdrawal 
from, prescribed medicines. 
 
The goal is to make sure that our healthcare system builds awareness and enhanced 
decision making for better patient treatment and support.  
 
These recommendations are just the beginning. All parts of the healthcare system and 
the general population will need to engage with this complex problem and work together 
to find solutions. The local strategic leadership of CCGs, sustainability and 
transformation partnerships and integrated care systems will be vital. 
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1. Introduction 
The commission and where it came from 
In October 2017 the minister for public health and primary care commissioned Public 
Health England (PHE) to identify the scale and distribution, and causes, of prescription 
drug dependence, and what might be done to address it. 
 
This commission followed representations by the All Party Parliamentary Group for 
Prescribed Drug Dependence (APPG PDD) and others, which came on the back of a 
long history of patient and other concerns, initially focused on benzodiazepines (and 
then also z-drugs), supported by the All Party Parliamentary Group on Involuntary 
Tranquilliser Addiction (APPGITA), but later extending to opioid pain medicines (and 
gabapentinoids) and antidepressants. 
 
The National Treatment Agency for Substance Misuse, and its successor in Public 
Health England, worked with the Department of Health on the issue of addiction to 
medicines, as it was then known, from 2011. This work supported medicine labelling 
changes and provided advice to those commissioning and providing treatment services. 
 
The minister’s 2017 commission also followed a report by the British Medical 
Association in 2015,1 and subsequent BMA-hosted roundtables, that expressed 
concerns about patients becoming dependent on, or suffering withdrawal symptoms 
from, some psychoactive medicines. The BMA reported that patients did not receive the 
support they needed, and the BMA promoted 3 recommendations: 
 
• the creation of a national helpline for prescribed drug dependence 
• an increase in provision of specialist support services 
• revised guidance for doctors on safe prescribing, management and withdrawal of 
prescription drugs 
 
In 2017, the Public Health Research Consortium (PHRC) reported on trends in what 
they termed “dependence-forming medicines”.2 These were benzodiazepines, z-drugs, 
gabapentin and pregabalin, and opioid pain medicines but not antidepressants. 
Although the PHRC study was able to use data in the Clinical Practice Research 
Datalink (CPRD) to report on the number and characteristics of a large sample of 
patients being prescribed dependence-forming medicines, including prescribing 
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The scope of the PHE review 
The scope of the review was published online at 
www.gov.uk/government/publications/prescribed-medicines-review-scope. 
Included in the scope were: 
 
• adults (age 18 and over) 
• dependence, withdrawal and, where the term was needed to ensure its inclusion in 
literature searches, discontinuation syndrome 
• the prescribed medicines benzodiazepines, z-drugs, gabapentin and pregabalin 
(sometimes called GABA-ergic or gabapentinoid medicines), opioid pain medicines 
(including codeine, although this is often bought over the counter as well as 
prescribed) and antidepressants (listed in appendix A) 
• prescribing in the community (medicines mainly prescribed in primary care and 
dispensed by community pharmacies, since this is how most patients obtain 
medicines); for completeness, the review also looked at prescribing in hospitals and 
care homes, and on private prescriptions 
 
The focus of the review, the limitations of available data and the need to keep any 
analysis and reporting both manageable and timely, meant excluding several related 
and overlapping issues of importance and concern, including the following. 
 
Under 18s 
The licensed indications for many medicines do not extend to young people and, as a 
result, more prescribing to young people is ‘off-label’ (not covered by the product’s 
marketing authorisation). The prescribing of the medicines included in the review to 
patients under 18 years of age is contentious and can be complicated by developmental 
issues and treatment of mental health problems. 
 
Over-the-counter medicines (except codeine as above) 
Some problems of dependence are initiated or maintained by the use of over-the-
counter medicines.3 Millions of patients find such medicines invaluable in self-treatment 
– and this frees up time that might otherwise be spent in GP surgeries – but some 
products are powerful and may lead to dependence.  
 
Secure environments including prisons (and secure hospitals) 
The policy and practice of prescribing medicines in these environments is complex and 
is described in appendix B. 
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The use of opioids for pain associated with cancer and at the end of life 
For some patients, shorter-duration prescribing of opioids is indicated in the alleviation 
of cancer pain during end-of-life care. Patients in remission from cancer, and those who 
have longer survival with cancer, may suffer from pain that is more difficult to treat.4  
 
The use of psychiatric medications in those with a learning disability, autism  
or both 
NHS England has a national project called STOMP (“stopping over medication of 
people with a learning disability, autism or both with psychotropic medicines”). These 
medicines are indicated for some people, but they may be associated with harm if used 
for too long, or at too high a dose, or for the wrong reason. 
 
Drug misuse 
Drug misuse has been excluded, except insofar as it involves prescribed medicines and 
is the result of prescribing. This is a complex and overlapping issue and is described in 
appendix B. 
 
Harms other than dependence and withdrawal that may be caused by the  
long-term prescribing of some medicines 
There is a very long list of possible harms arising from the long-term use of some 
medicines, including death. These are reported through the MHRA Yellow Card scheme 
and included in summaries of product characteristics (SmPCs) and patient information 
leaflets (PILs). These harms were excluded from the review unless evidence could be 
identified that pointed to dependence and withdrawal.  
 
Some medicines with no marketing authorisation 
The use of some medicines with no marketing authorisation (unlicensed), or use outside 
their marketing authorisation (off-label), in the UK has not been separately or 
specifically considered. It is not distinguished in the data, so is included, and it was not 
excluded from the rapid evidence assessment (REA). Some off-label or unlicensed 
medicine is appropriate, inevitable and helpful where good evidence exists on clinical 
benefit (and where there is no alternative). But it may also be riskier than using a 
licensed medicine as authorised, and could contribute to dependence and withdrawal. 
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Medicines prescribed or otherwise supplied by independent online doctors and 
pharmacies in this country and abroad 
There is legitimate concern in relation to the safe supply of opioid medicines by 
websites based inside and outside the UK, and the unlawful online supply of 
prescription medicines. The focus of the PMR is on prescribing by GPs to their patients 
in the community in England. Concerns about online prescribing and supply are 
receiving attention from the Medicines and Healthcare products Regulatory Agency 
(MHRA), the Care Quality Commission (CQC) and the General Pharmaceutical Council 
(GPhC). Recent guidelines from the GPhC are designed to better regulate online 
prescribing and online pharmacies www.pharmacyregulation.org/news/new-safeguards-
people-seeking-medicines-online 
 
Co-proxamol and other medicines 
Co-proxamol and other medicines that are no longer available to be prescribed in the 
UK other than off-label or unlicensed have also been excluded. 
 
The context of the review 
In the following section, a brief narrative is presented on each medicine class included 
in the review. This summarises the origins of each class and outlines research on 
identified harms, dependence or withdrawal. It should be noted that there will always be 
challenges for reliable measurement of incidence, severity and duration of adverse 
effects of medication due to the nature of the patient samples studied and the criteria 
used to assess symptoms.  
 
Some medicines in the review share a common process when used longer-term, in 
which the patient becomes tolerant to the prescribed dose and requires more of the 
drug to achieve a desired effect. There may be cross-tolerance with other drugs and 
alcohol. Once tolerant, taking more of a medicine can increase the risk of dependence, 
and the patient may struggle to follow the prescriber’s instructions on frequency and 
dosing. Some patients in this situation may be motivated to buy medicines or drugs 





During the 1950s, 1960s and 1970s benzodiazepines became the global, front-line 
medication treatments for anxiety and insomnia. There was an initial perception that 
they had a low toxicity profile and carried a negligible risk of dependence.5 
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Benzodiazepines rapidly replaced an older generation of barbiturate medicines, which 
had a high toxicity/overdose profile. Other uses of benzodiazepines include muscle 
relaxation and control, pre-surgical anaesthesia and the management of alcohol 
withdrawal.6-8  
 
Relatively short-term randomised controlled trials established the anti-anxiety and sleep 
induction therapeutic action of benzodiazepines. Initially, there was limited data on long-
term effects, but widespread concern grew rapidly, with warnings that a distinct pattern 
of withdrawal symptoms could arise when medication was stopped abruptly.9  
 
Adverse effects in the short term 
 
Benzodiazepines may achieve a therapeutic effect but in the presence of unwanted 
residual effects. The most common adverse effect is over-sedation (drowsiness, 
tiredness) and impaired of cognitive function. Some patients have reported feelings of 
increased aggression and problems with emotional and behavioural regulation. These 
adverse effects can diminish after a week or so and with a lower dose. Benzodiazepines 
enhance the sedative effects of opioids and antidepressants (and other drugs) and use 
of alcohol is not advised. Association studies have reported a link between 
benzodiazepines and road traffic accidents10 and accidents and cognitive problems in 
the elderly.11, 12  
 
Some patients who take benzodiazepines in the medium term, and then discontinue, 
report ‘rebound symptoms’. These take the form of increased anxiety and sleep 
problems (compared to when the medication was started). These symptoms may last 
about 4 weeks (although since the 1980s there have been reports of patients who 
experience prolonged symptoms over several months13). Longer-acting 
benzodiazepines appear to carry a greater risk of these aversive rebound symptoms. 
These symptoms may make the patient fearful of discontinuing benzodiazepines. 
 
Risk of dependence  
 
In the 1970s case studies began to be reported of patients who experienced 
benzodiazepine dependence.14 Psychological symptoms were reported including 
frequent intrusive thoughts accompanied by strong urges to obtain medicine, with 
behavioural problems with controlling how often and how much medicine was taken.15 
However, there are no accurate prevalence estimates of prescribed benzodiazepines 
being used not-as-directed (given the largely hidden nature of the sub-population 








In the UK in the early 1980s there was intensive media attention on problems of 
withdrawal from benzodiazepines, especially from lorazepam. At that time, clinical 
evidence indicated that severe withdrawal complications on cessation could be 
experienced by patients who were – at that time – considered be receiving lower doses 
(such as about 30mg of diazepam equivalent).16 
 
Case report evidence shows that, at higher doses of benzodiazepines taken for around 
2 months or longer, most patients will experience characteristic withdrawal symptoms if 
the medication is stopped abruptly. These symptoms commonly include increased 
anxiety and insomnia (which may be hard for the doctor and patient to attribute to a 
return of the original anxiety disorder or as a symptom of withdrawal). Other symptoms 
may also be experienced including dizziness, loss of appetite, dry mouth, nausea and 
muscle weakness, and severe symptoms including vomiting, hyperthermia, headache, 
muscle pain, convulsions, confusion, and perceptual sensory disturbances. These 
reactions are usually pronounced during the few days after medication has been 
stopped. For some patients – if there is no resumption of benzodiazepine use – 
withdrawal symptoms will peak in severity after 2 weeks and return to pre-withdrawal 
levels by 4 weeks.17 
 
It is reasonable to believe that a good clinical course and low relapse rate can be 
expected for most patients. However, some report symptoms, which they attribute to 
stopping benzodiazepines, for 1 to 2 years or more, although usually with diminishing 
intensity.18, 19 Others describe devastating and adverse reactions to benzodiazepine use 




Clinical guidelines have been developed to guide effective use of benzodiazepines and 
the medical management of benzodiazepine withdrawal.  
 
The first formal statement was made in 1988 by the Committee on Safety of Medicines 
(CSM), recommending that benzodiazepines should only be used at the lowest dose 
possible and: 
 
• for anxiety, for no more than 2 to 4 weeks, only for severe and disabling anxiety 
• for insomnia, prescribed intermittently for no more than 4 weeks, only for severe and 
disabling insomnia20 
 
The Royal College of Psychiatrists (RCPsych), in 1988 and 1997, and the Mental Health 
National Service Framework, in 1999, endorsed the CSM guidance. A joint statement 
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from the RCPsych and the British Association for Psychopharmacology was issued in 
2013.21 
 
The general advice before prescribing benzodiazepines is to always consider the risk of 
harmful effects against the potential benefits from short-term or intermittent use, and to: 
 
• judge alternatives including referral for psychological therapy, since the first-line 
intervention for generalised anxiety disorder, panic disorder and panic attacks is 
Cognitive Behavioural Therapy (CBT) 
• where a benzodiazepine is indicated, inform the patient that treatment will be at the 
lowest effective dose for as short a time as possible (2 to 4 weeks) 
• make the first prescription for no longer than 7 to 14 days, with no issue of a repeat 
prescription 
• offer support for long-term patients in the form of a slow and gradual reduction in 
dosing (taper) to avoid withdrawal symptoms 
 
Benzodiazepines should be avoided in patients with significant pulmonary disease, 
respiratory depression, obstructive sleep apnoea, and severe hepatic disease, and for 
those taking other hypnotics, (tricyclic) antidepressants, antihistamines, and opioids. 
 
Medical management of benzodiazepine withdrawal should be individually tailored to 
the patient. It usually often involves switching to a longer-acting benzodiazepine, 
prescribed on a slow dose taper, maintaining the dose if symptoms become 
uncomfortable or increasing the dose if symptoms become intolerable, and sometimes 
with additional prescribing for symptomatic relief.  
 
NICE’s Clinical Knowledge Summary for benzodiazepines and British National 
Formulary advice have been adapted from a protocol developed by Heather Ashton.22 
They give detailed guidance on how to consult a patient who will need support to 
discontinue, and note that the taper for some long-term benzodiazepine patients usually 
involves a stepwise transfer to an equivalent daily dose of diazepam, then reducing the 
dose by 1 to 2mg every 2 to 4 weeks. The dose in patients taking high doses of 
benzodiazepines may need to be reduced by up to one-tenth every 1 to 2 weeks. If 
uncomfortable withdrawal symptoms occur, maintain this dose until symptoms lessen. 
Reduce diazepam dose further, if necessary in smaller steps – 500 microgram steps 
may be appropriate towards the end of withdrawal. For long-term patients, the period 




Benzodiazepines are effective in the short-term treatment of acute and severe anxiety. 
For patients with chronic anxiety or insomnia, chronic use of benzodiazepines risks 
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tolerance to drug effects, dependence and withdrawal symptoms. Patients taking 





Introduced in the 1990s, 3 medicines (zopiclone, zaleplon and zolpidem), known as the 
‘z-drugs’, and licensed only for insomnia, became commonly used (zaleplon no longer 
has a marketing authorisation in the UK). Insomnia is diagnosed as a chronic 
disturbance of normal sleep pattern and is associated with reduced quality of life and 
mental health problems.24 CBT has been shown to be an effective treatment for 
insomnia.25 
 
Chemically different from the benzodiazepines, z-drugs are hypnotics and were 
developed with the aim of working faster and clearing quicker from the body, to prevent 
day-time sleepiness, and as a safer alternative to benzodiazepines with a low risk of 
dependence, especially in elderly patients.26 27 
 
Adverse effects in the short term 
 
In experimental laboratory studies zopiclone has the potential to induce residual 
sedation and impaired driving performance and accidents,28, 29 although driving after 4 
hours following night-time dosing of zaleplon (a very short-acting medication with an 
elimination half-life of one hour) appears to not be affected.29 As would be expected, the 
risk to driver behaviour increases with dose and the use of longer half-life products, and 
during the first few weeks following medication initiation.30 Interpretation of 
epidemiological research on the driver safety profile of people taking z-drugs is 
hampered by variation in design and study quality. There is an association with female 
users of zolpidem who are 80 years or more,31 but the effect for zopiclone is mixed.10, 32 
It should be borne in mind that there is a risk of confounding by indication: people who 
suffer from insomnia are more at risk of traffic accidents,33 and the detection of a drug 
metabolite in (say) a urine sample does not pinpoint the time of consumption. 
 
As with the benzodiazepines, there is some evidence of a dose-response relationship 
between the z-drugs and balance.34, 35 Association studies of falls and fractures report 
an association with z-drugs and, as would be expected, is a more pronounced risk 
among older people and those with mobility problems. The research data is sparser 
here than for benzodiazepines. The 2 most recent reviews estimate that the use of 
zolpidem is associated with an increased risk of fracture (relative risk 1.92, 95 % CI 
1.65-2.24)36 and injury (odds ratio 2.05, CI 95%: 1.95–2.15)37, so there is reliable 
evidence for caution in the use of this medicine with people at risk of fractures. 
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Risk of dependence and withdrawal 
 
There have been many reports of adverse/paradoxical cognitive and psychomotor 
reactions associated with z-drug use, and it is now recognised that they have the risk 
profile as benzodiazepines. As with the benzodiazepines, there is some evidence that z-
drugs may be prescribed for longer than guidelines recommend.38 Characteristic 
withdrawal symptoms are reported for zopiclone and zolpidem and include insomnia, 
headaches, confusion, anxiety and restlessness.39 
 
There is also some evidence that GPs have more positive beliefs about the efficacy of 
the z-drugs, and their lower side-effect profile, compared to benzodiazepines.40 




In 2014, the European Medicines Agency advised that the recommended dose for 
zolpidem should be a single dose before sleep, and driving should be avoided for the 
next 8 hours.41 Z-drugs have the potential to lose any therapeutic effect over time and 
cause tolerance and a risk of dependence, so the summary of product characteristics 
(SmPC) advises against long-term use: prescription should be for as short a time as 
possible and not exceed 2 weeks, including a taper, for zolpidem 
(www.medicines.org.uk/emc/product/3976/smpc), not more than 2 to 5 days for 






Depression is common and a leading global cause of social and occupational 
impairment (some £7.5 billion in social costs in England in 2007).42 In the UK, the 
prevalence of depression rose from 2.6% in 2007 (and 2.2% in 1993) to 3.8% in 2014.43 
 
More severe forms of depression represent a sustained extreme exaggeration of normal 
negative human experience – with feelings of sadness, irritability and emptiness or loss 
of pleasure, accompanied by other symptoms that significantly affect the individual’s 
ability to function.44 Typically, a depressed person loses confidence, interest and 
pleasure in activities; experiences reduced sleep and weight loss, and develops a 
prominent and chronic negative thinking style. Very severe depression may be 
accompanied by psychotic symptoms (including hallucinations and delusions). 
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Depression is associated with episodes lasting several weeks or months and with a risk 
of recurrence (10.3% in one USA estimate45). Clinicians are advised to use a patient-




The history of medical treatment for depression lies in the discovery that iproniazid and 
imipramine compounds increase mood. The first-generation antidepressants included 
tricyclic antidepressants and monoamine oxidase inhibitors, but these were often 
associated with side-effects and a risk of overdose toxicity. Contemporary 
antidepressants are based on selective serotonin, or serotonin and noradrenaline, 
reuptake inhibition (SSRI and SNRI, respectively). Antidepressant medicines may also 
be used to treat other conditions, such as mild depression, phobias, anxiety and 
neuropathic pain. 
 
Overall, since the launch of the SSRI/SNRI products, the use of antidepressants to treat 
depression has been increasing in many Western countries. In the USA, the national 
prevalence of antidepressant use increased from 6.5% in 1999 to 2000 to 10.4% in 
2009 to 2010.47 In the UK, Middleton and colleagues used GP data on antidepressant 
prescribing from the Medical Data Index published by Intercontinental Medical Statistics, 
reporting that there was a two-fold increase in the number of antidepressant 
prescriptions issued from 1975 to 1998 (and a three-fold increase between 1988 and 
1998 mainly due to the SSRIs), and this appears to be associated with an increase in 
the proportion of patients enrolled in long-term treatment.48 
 
For the period 1993 to 2005, a descriptive study using the GPRD reported that most 
antidepressant prescriptions were issued to patients receiving long-term treatment for 
depression or intermittent treatment (several episodes of recurring or relapsing 
depression).49 An observational cohort study of 78 urban GP practices in Scotland 
selected data on all patients in 2009 to 2010 and reported that 47.1% received an 
antidepressant (except amitriptyline given for neuropathic pain) for 2 years or more.50 
More recent findings are reported in the later section on the review’s analysis of 
prescription data. 
 
Antidepressants can be transformative in severe depression, but there have been 
claims and counter-claims for their efficacy.51-54  
 
Unlike the other medication classes included in the review, there is little evidence that 
antidepressants carry any significant risk of dependence. A report by a Committee on 
the Safety of Medicines expert working group in 2004 concluded that all SSRIs may be 
associated with withdrawal reactions, some severe and disabling to the individual, but 
also that there was no clear evidence that they have any “significant dependence 
liability”, with no significant tolerance induction, and they do not appear “to lead to 
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craving in comparison with other drugs of dependence [and that] there is no clear 
evidence of impaired control”.55 
 
Risk of withdrawal 
 
There have been many reports of withdrawal symptoms following cessation of 
antidepressants. These withdrawal symptoms appear to be highly variable in terms of 
onset, degree of severity and duration. Typically, they last a few weeks, but there is 
substantial patient variability. Berber56 coined the mnemonic ‘FINISH’ to capture the 
symptoms: 
 
F: flu-like symptoms – lethargy, fatigue, headache, achiness, sweating 
I: insomnia – and including vivid dreams or nightmares 
N: nausea – and sometimes vomiting 
I: imbalance – dizziness, vertigo, light-headedness 
S: sensory disturbances – ‘burning’, ‘tingling’, ‘electric-like’ or ‘shock-like’ sensations 
H: hyperarousal – anxiety, irritability, agitation, aggression, mania, jerkiness 
 
One of the first reports of withdrawal was a study of patients who stopped taking the 
tricyclic imipramine.57, 58 Later it was estimated that, among patients who take all types 
of antidepressants continuously for one month or more and then stop, markedly reduce 
their dose or taper, up to approximately 20%59 would experience symptoms of what was 
originally termed a ‘withdrawal phenomena’ or ‘withdrawal reaction’60, 61 and has also 
been termed ‘antidepressant discontinuation syndrome’ (see glossary). A relapse of 
depressive symptoms can also follow antidepressant cessation, but the onset of mood 
disorder symptoms is usually longer than withdrawal. Among the SSRIs/SNRIs, 
paroxetine and venlafaxine may have a greater likelihood to cause withdrawal effects 
due to their short half-life.55 
 
For the SSRIs, Fava and colleagues reported a systematic review of a mixed set of 61 
investigations.62 No estimation was reported given differences in research design and 
patient populations and case identification. The authors concluded that withdrawal 
symptoms can follow any type of SSRI but appear to be much more frequent with 
paroxetine. A recent systematic review of 14 studies estimated that between 27% and 
86% (weighted average 56%) of people who discontinue antidepressants experience 
withdrawal effects (46% reporting these to be ‘severe’).63 This review identified that 7 of 
10 studies observe that a significant proportion of patients will experience withdrawal 










A recent study reported on findings from an online survey by the mental health charity, 
Mind, of 752 people with experience of long-term antidepressant treatment.64 The 
majority were women (76.1%). 
 
“Most participants had either come off antidepressants (34%) or had tried and failed 
(36%). Of those still taking them 76% had been doing so for at least a year and 36% for 
5 years or more. 26% expected to take them forever. About half (48%) did not have 
their drugs reviewed at least every 3 months. Most (65%) had never had a discussion 
with the prescriber about coming off. Nearly half (45%) of those who had stopped the 
drugs had done so without consulting their doctor. However, of those who came off after 
consulting their doctor, the majority (65%) experienced the doctor to be supportive.” 
 
A range of patient experiences has been amassed for a broad narrative review of 
observational and qualitative studies of antidepressants since 1990 by Gibson, 
Cartwright and Read.65 Qualitative studies can shed light on patient experiences and 
perspectives, but issues of representativeness cannot be addressed. The authors note 
research that indicates that people with more severe depression may have more 
positive attitudes towards antidepressants than those with less severe depression. For 
example, a prospective follow-up study in Finland found that patients reported mainly 
positive attitudes over 5 years.66 
 
Themes reported in the Gibson et al review include: 
 
• patients’ fears that antidepressants may be addictive 
• that some will state a preference for psychotherapy over antidepressants 
• that insufficient information is given about antidepressant effects 




There are clinical guidelines on first and second line prescribing choices,67 but no 
recommended limits on duration. It may take several weeks for depressive symptoms to 
improve, and continued prescribing from 6 months after remission to 2 years or more is 
indicated.67 
 
The National Institute for Health and Care Excellence (NICE) is reviewing the evidence 
for its planned guideline on ‘Depression in adults: treatment and management’ and is 
scheduled to publish in 2020.68 
 
Recently, Horowitz and Taylor reviewed tapering procedures to mitigate withdrawal 
symptoms associated with SSRIs.69 They cite evidence from PET studies that may 
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favour tapers conducted over a period of months that help the patient reduce to low 
dosage levels (well beneath the therapeutic dose). This report has stimulated debate on 
the need for better research, with consensus that the rate of tapering should be tailored 




Antidepressant medicines have been very extensively studied and many products are 
licensed. Prescriptions have been increasing, particularly for longer-term treatment. 
There is little evidence that antidepressants carry any significant risk of dependence, 
but there is now widespread recognition that antidepressants are associated with 
withdrawal symptoms in many patients. Patients who take antidepressants over the 
longer term and who wish to discontinue will likely require careful medical management 
and support. 
 
Opioids for chronic, non-cancer pain 
Overview 
 
Chronic non-cancer pain (CNCP) is an aversive sensory experience (either continuous, 
intermittent or provoked) and a common presentation in primary care and specialist 
medical services. It is a major public health problem associated with significant patient 
distress, decreased quality of life, impaired personal and social functioning and high 
social costs. There has been no firm definition of chronic pain and researchers have 
operationalised it in different ways. However, the new version of ICD-11 (a widely-
accepted, worldwide system of medical coding) defines it as pain that lasts or recurs for 
more than 3 months.44 
 
Arguably, the origin of the current concerns about long-term opioid prescribing (and the 
epidemic of actual harm in North America) lies in the perception, promoted by some 
pharmaceutical manufacturers and clinical societies, that chronic pain in the general 
population was under-treated.70, 71 There was also an early controversy as to whether 
opioids represent an effective treatment for chronic pain or a significant risk for non-
medical use,72 iatrogenic addiction73 and opioid-induced hyperalgesia.74 
 
Pharmacotherapies for chronic pain associated with low back pain (probably the most 
commonly reported)75, along with injury-related and degenerative joint disease, include 
peripherally-acting non-steroidal anti-inflammatory medicines and centrally acting 
opioids. There is a view that a sub-population of chronic pain patients can be prescribed 
long-term opioids at relatively stable doses so that their analgesia and functioning can 
be maintained with good adherence and tolerable side-effects. 
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Risk of dependence and withdrawal 
 
From the 1990s onwards, pain specialists debated the role of opioid therapy in chronic 
pain and the balance of initial benefit and cumulative risk. Assessing risk has been 
hampered by considerable variation in conceptual and measurement approaches, with 
contradictory reports of the scale of abuse and other harms associated with increased 
prescribing of opioids. 
 
However, since the end of the 1990s, use of opioid medicines for chronic pain has 
become increasingly controversial, with concerns expressed about safety and efficacy 
and the potential for patient harm (risk of overdose, so-called aberrant drug-related 
behaviours, and addiction [opioid use disorder]), but rates of prescribing continued to 
rise in several countries worldwide.76 
 
In the UK, concerns have been expressed about a steep rise in the number of 
prescriptions for many opioid pain medicines (Evening Standard, The Times, etc). Some 
have pointed out that only counting prescriptions (or tablets) misses an even steeper 
increase once medicine strength (and therefore dosing) is taken into account.77 This 
shows increasing use of strong opioids in the past 10 years such that the rate of 
increase in the total amount of morphine-equivalent opioids prescribed has been even 
greater than that of prescription numbers. 
 
In the United States, after relatively low rates from the mid-1960s, from the mid-1990s 
to the end of the decade there was a four-fold increase in new users of opioids (from 
628,000 to 2.4 million), and an increase of 135% (from 1995 to 2002) in emergency 
hospital admissions involving opioids.78, 79 
 
Commentators at that time raised concerns that pharmaceutical opioid use (in particular 
OxyContin) could lead to heroin use.80 In their early report, Siegal and colleagues 
described a small convenience sample of patients who had experienced tolerance to 
the tablets’ effects and physical withdrawal symptoms and reported that they had to 
resort to using heroin when deprived of OxyContin and had found heroin to be readily 
available and less expensive. 
 
Some patients in long-term opioid treatment report concerns associated with the 
medication. For example, the Prescribed Opioids Difficulties Scale (PODS)81 assesses 
perceived problems and concerns due to taking opioids, including: losing interest in 
activities, trouble with concentration or memory, over-sedation, low mood and anxiety 
symptoms, occupational, family and social problems, cognitive problems, risky 
behaviour (such as driving while feeling sleepy or less alert), and concerns about 
opioids (preoccupation, feeling could not control use, needing higher doses, worry might 
be dependent or addicted, and wanted to stop or cut down.  
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A hospital study of 414 patients in Sweden, reported that 13% were diagnosed with 
current opioid dependence and 2% with current opioid misuse.82 Ives and his 
colleagues conducted a prospective clinical study of patients enrolled in long-term 
opioid treatment for chronic pain. Using an operational definition of 12-month during-
treatment opioid misuse, among 199 consecutive patients opioid misuse was recorded 
for 62 (32%) during 12 months of treatment.72 
 
Risk of long-term opioid treatment after surgery 
 
Using administrative data linkage in Ontario, Alam and colleagues identified older adults 
(aged 66 years and above) who had an opioid prescription dispensed within 7 days of a 
short-stay surgical procedure and then had a prescription dispensed for an opioid within 
60 days of the 1-year anniversary of the surgery.83 
 
In a recent Australian community sample study of long-term opioid treatment for chronic 
pain, people who rated themselves as having more prescription-related problems and 
concerns on the PODS tended to be younger and had poorer physical health and had 
greater pain severity.84 
 
A range of drug-related behaviours that are not medically directed may reflect self-
directed treatment. These behaviours may include: 
 
• taking more of a prescribed opioid than prescribed or by a non-authorised route of 
administration 
• request that a prescription be re-filled early 
• seeking other treatment 
• taking medication prescribed to another person 
• taking over-the-counter medicines 




NICE has issued guidelines for the use of pharmacological treatments of central and 
peripheral neuropathic (nerve) pain.85 It is important to note that this can include 
neuropathic cancer pain. Other than trigeminal neuralgia, NICE recommends that the 
physician offer the patient a first-line choice of amitriptyline, duloxetine, gabapentin or 
pregabalin. If this initial treatment is not accepted or effective, one of the remaining 3 
drugs should be considered, with further switching as required. Tramadol is 
recommended only if an acute rescue therapy is indicated. 
 
The NICE guideline on low back pain and sciatica recommends that weak opioids (with 
or without paracetamol) are reserved for managing acute low back pain only when a 
non-steroidal anti-inflammatory drug (NSAID) is contraindicated, not tolerated or has 
been ineffective. The guideline recommends that opioids should not routinely be offered 
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for managing acute low back pain and should not be offered for managing chronic low 
back pain.86 
 
The PHE-supported Opioids Aware online resource (www.rcoa.ac.uk/faculty-of-pain-
medicine/opioids-aware) from the Faculty of Pain Medicine at the Royal College of 
Anaesthetists reflects NICE and other guidance, and expert clinical opinion, and is 




The process of tolerance-driven dependence has led opioids to become a major public 
health crisis in many countries. Opioids have a role in short-term prescribing for acute 
pain, but non-opioid medicines and other supports have often been overlooked. For 
most people with chronic non-cancer pain, opioids do not provide adequate clinical 
benefit when balanced against the risks of dependence and overdose poisoning, and 
harms to others in the community. As with the benzodiazepines and antidepressants, 
patients who have been prescribed to long-term and who wish to discontinue may need 





The gabapentinoids (pregabalin and gabapentin) are analogues of the neurotransmitter 
γ-amino butyric acid (GABA) but they do not have direct action on GABA 
neurotransmitters. In the UK, gabapentin was first authorised in 1997 for seizure control 
and later for neuropathic (nerve damage) pain.85 Pregabalin has relatively higher 
potency and absorption rates and, as well as neuropathic pain, is also licensed for 
generalised and social anxiety disorder. They are also used, as are opioids, as second-
line treatments for restless legs syndrome. In the USA, despite any evidence for 
efficacy, there has been off-label prescribing for other pain conditions, attributed in one 
study to industry marketing efforts.87 Shanthanna et al reported a systematic review of 8 
randomised controlled trials and concluded a lack of efficacy and significant risk of drug-
related adverse events.88 
 
In terms of effectiveness, the latest update of the Cochrane review of 37 studies on 
5,914 participants with a typical duration of treatment of 4 to 12 weeks has only 
moderate quality evidence (mainly due to small sample size).89 The review concludes 
that gabapentin is effective for shingles-related pain: 32% with substantial benefit (at 
least 50% pain intensity reduction or pain rated as very much improved) versus 17% for 
placebo. On the same outcome measure for diabetic neuropathy the findings were 38% 
versus 21%. Some patients with these problems may experience drug-related adverse 
events and some who tolerate the drug will not derive clinically meaningful benefit. 
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Onakpya et al reported a systematic review of the benefits and harms associated with 
pregabalin.90 Using data from 28 trials with 6,087 participants (evidence collectively 
rated as of low quality), patients receiving pregabalin achieved significant reductions in 
pain (standardised mean difference (SMD) − 0.49 on a subjective numerical rating scale 
compared with placebo). Pregabalin was associated with a risk of adverse events 
compared with placebo and this was associated with discontinuing treatment. 
 
Gabapentinoids can cause reinforcing subjective effects, including euphoria, sedation 
and dissociation, and may be sought as a recreational drug.91 Smith et al highlighted 
the risk of medication diversion92 and Piskorska et al suggest that gabapentin is 
associated with the highest risk of non-medical use among all antiepileptic medicines (in 
Poland).93 This appears to be the case in Scotland but, in other parts of the UK, 
pregabalin is more commonly misused. 
 
In a review of 59 studies, Evoy et al concluded that there is sufficient evidence to 
indicate that these drugs can be used for non-medical reasons.94 The authors 
concluded that there is a risk that patients will self-administer higher than recommended 
doses to achieve reinforcing effects (estimating a 1.6% prevalence of gabapentinoid 
abuse in the general population and a prevalence from 3% to 68% among populations 
with opioid use disorder (and additional risk factors including other mental health 
problems). There is also increasing evidence that, when used with opioids, a dangerous 




PHE and NHS England issued advice for prescribers in 2014 on the risk of misuse of 
pregabalin and gabapentin, and advised caution in prescribing, especially co-
prescribing, and dose tapering.96 Gabapentinoids have come to be used for a wider 
range of indications than is supported by the evidence or their licensing, and they have 
sometimes been prescribed in place of opioids or benzodiazepines in the likely-
mistaken belief that they are less liable to misuse or dependence, and lack of 
awareness of the withdrawal problems that can arise when prescribing is stopped. 
 
A repeating pattern? 
What can be seen throughout many of these narratives is a story that occurs 
repeatedly: a new medicine arrives that offers benefits over existing medicines and is 
promoted as the hope for better treatment with fewer problems. Problems with the new 
medicine are quickly reported by some patients and doctors but are ignored or denied, 
or the evidence is just lacking for some years because the research is not done. 
Eventually enough reports and evidence accumulate that the problems are 
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acknowledged and then the search is on for something better and safer… and the 
pattern repeats. 
 
Clearly there are many highly effective medicines and many that have brought about 
transformative improvements in the lives of some patients. But it is remarkable how 
often the pattern above repeats. It happened when benzodiazepines replaced 
barbiturates, and when z-drugs replaced benzodiazepines for insomnia. And it may be 
happening now as gabapentinoids are used to replace opioids for some forms of pain.  
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2. The methodology of the review 
Methods for the review are described in more detail in this section, and in greater detail 
in technical appendices or supplementary report, but in summary they included: 
 
• mapping of medicine categories, conditions and guidance 
• an initial literature scoping search 
• an expert group to advise on methods and content of final report 
• analysis of prescription and GP patient data 
• a call for papers and evidence, including published research and reports in the grey 
literature (these are reports published by organisations outside of commercial or 
academic channels), including those that collate personal experiences 
• a literature review to summarise the evidence on causes, harms and effective 
prevention and treatment, which was independently peer reviewed 
• this report of the evidence review, which has been independently peer reviewed 
 
Mapping the medicines 
As a first step in scoping the review, and particularly the prescription data analysis, PHE 
commissioned the National Institute for Health and Care Excellence to map the 
medicines covered by the 5 broad classes to be included: benzodiazepines, z-drugs, 
opioid pain medicines, gabapentinoids and antidepressants. 
 
NICE produced a detailed table showing the individual medicines to be included, their 
legal category, indications, usual dose, index events (when, in a patient’s condition or 
journey, they might be prescribed, or reviewed, or dose increased/decreased/ceased) 
and any recommended limits on duration of prescribing, with the latter 2 informed by the 
manufacturers' statement of product characteristics (SmPC), British National Formulary, 
NICE guidance and, in the case of opioids, the Opioids Aware online resource from the 
Faculty of Pain Medicine. 
 
The full mapping is available separately as an Excel spreadsheet via the project web 
page. 
 
Literature scoping search 
PHE’s knowledge and library service conducted a scoping search to gain insight into the 
range and depth of the research on prescribed medicines to inform the commissioning 
of the rapid evidence assessment. The databases Embase (1996 - 2018 week 12), 
Medline (1946 - March 19, 2018) and PsycINFO (2002 – March week 3) were searched 
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for literature since 2007 on the prescribing patterns, risks of dependence and 
withdrawal, outcomes and interventions relating to antidepressant and pain medicines. 
 
The search strategy for this scoping search is detailed in appendix C. 
 
Expert reference group 
An expert reference group (ERG) was recruited to support the project. Membership was 
by invitation to a broad range of people with relevant expertise from a range of 
professional backgrounds. In addition, 3 experts by experience were invited. All 
members completed a declaration of interest and this was made publicly available via 
the project web page, along with ERG meeting notes and project documents. 
Secretariat to the ERG was provided by PHE. The role of the ERG was to contribute to 
the success of the project by: 
 
• informing the approach and provide support for the project as a whole 
• ensuring advice is available on the key issues 
• commenting on draft versions of the written report  
• advising on the quality, limitations and appropriate use of evidence 
• highlighting relevant practice and implementation issues relevant to the PMR and 
signposting the PMR team to further information on such issues 
• ensuring a focus throughout on how the findings will be used and presented 
• assisting the development of PHE’s recommendations, ensuring they are realistic 
and based on the strongest interpretation of findings from the PMR 
 
The full ERG met 3 times during the review, individual members responded to specific 
questions relevant to their areas of expertise, and smaller group meetings were held to 
discuss the data analysis and the published evidence. 
 
The review’s data analyses 
No single source of data, or analysis of it, can provide an accurate and comprehensive 
picture of the scale of dependence on and withdrawal from the medicines covered in the 
review. The report uses a mix of data and analyses to paint as complete a picture as 
possible. Each data source and analysis has strengths and weaknesses which are: 
 
• NHSBSA data on all community-dispensed NHS prescriptions in England since April 
2015, when patient identifiers were introduced, can identify numbers prescribed, and 
enable estimation of polypharmacy, duration, etc. - Appendix D describes the 
analysis plan for this data 
• Longer-term Prescription Cost Analysis data from NHSBSA also has all community-
dispensed NHS prescriptions in England but activity cannot be linked to patients so 
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is useful for showing trends in prescribing over a longer time but not patient numbers 
or other patient factors. Data is analysed back to 2008 
• IQVIA provided 3 data sets on prescriptions and dispensing not covered above: 
• care homes (2016 to 2018) 
• hospitals (2013 to 2018) 
• private prescriptions (2016 to 2018) 
 
These only provide units and values prescribed or dispensed – and they are small 
compared to NHS prescriptions dispensed in the community – but they provide further 
evidence of volume of, and recent trends in, prescribing to compare with that for NHS 
community prescriptions. 
 
Findings from these analyses are in chapter 3 and a detailed technical annexe 
accompanies the report. 
 
Clinical Practice Research Datalink analysis 
The Clinical Practice Research Datalink (CPRD) contains long-term prescribing data for 
patients in primary care but is only a sample. It has not been analysed as part of the 
review – it had already been analysed for some of the medicines in the review by the 
Public Health Research Consortium (PHRC) in 2017 and this analysis was updated and 
expanded in 2019 to: 
 
• include additional analyses of prescribing duration  
• add data on over-the-counter sales of some medicines 
• append a critique of other estimates of prevalence 
• additionally, and separately, report on antidepressants 
 
PHRC’s analysis was commissioned by DHSC separately to the review, and formed no 
part of it, but draft findings were able to inform those of the review and are summarised 
in chapter 3. 
 
Rapid evidence assessment 
The REA of articles published between 2008 and 2018 was commissioned externally 
via an open tender process which started in June 2018. The specification for the 
literature review was drafted by the PHE project team and commented on by the expert 
reference group. The contract started in August 2018 and the work finished in February 
2019.  
 
The National Guideline Centre (NGC) was awarded the contract based on their skills, 
experience in undertaking this kind of review and understanding of the potentially 
contentious nature of the topic. The NGC is hosted by the Royal College of Physicians 
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(RCP) and has governance partnerships with the Royal College of Surgeons of 
England, Royal College of General Practitioners, Royal College of Nursing and the 
RCP. 
 
PHE worked closely with NGC formally in monitoring meetings, ensuring the work 
progressed, answering queries relating to the specification, or utilising PHE clinical 
advisers. 
 
Frameworks guided the literature searching process, critical appraisal and synthesis of 
evidence. Review questions for harms, interventions and current practice were 
developed using a PICO framework (population, intervention, comparison and 
outcome). The risk factors review question was developed using a framework of 
population, presence or absence of factors under investigation (for example, prognostic 
factors) and outcomes. The patient's experience question was developed using a 
framework of population, setting and context for qualitative reviews. 
 
NGC undertook a rapid evidence assessment (REA), carrying out literature searches of 
the Cochrane Library, Epistemonikos, Database of Promoting Health Effectiveness 
Reviews, Health Evidence, Medline, Epub Ahead of Print, In-Process & Other Non-
Indexed Citations and Daily, Embase, PsycINFO, Health Technology appraisals, Trials 
Register of Promoting Health Interventions, and Applied Social Sciences Index & 
Abstracts looking for studies of dependence, short term discontinuation or longer term 
withdrawal symptoms from the following prescribed medicines: opioids for chronic pain 
(excluding end of life /palliative care/cancer pain), benzodiazepines, z-drugs, 
gabapentin and pregabalin (excluding epilepsy treatment), and antidepressants. Each 
study included was critically appraised for risk of bias, and the quality of evidence 
assessed for each review theme. 
 
A level of confidence for the review findings was given, based on the GRADE-CERQual 
system which uses 4 levels of confidence: high, moderate, low and very low. Four 
components (methodological limitations, coherence, relevance and adequacy) are 
assessed for each paper in combination to form an overall judgement on the level of 
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Table 1: Overall level of confidence for a review finding in GRADE-CERQual 
explained 
Level  Description 
High 
confidence 
It is highly likely that the review finding is a reasonable representation of 
the phenomenon of interest 
Moderate 
confidence 
It is likely that the review finding is a reasonable representation of the 
phenomenon of interest 
Low 
confidence 
It is possible that the review finding is a reasonable representation of the 
phenomenon of interest 
Very low 
confidence 
It is not clear whether the review finding is a reasonable representation 
of the phenomenon of interest 
 
The methods for each of the 5 questions included in the REA differ slightly and are 
detailed in table 2 below. Searches were limited to the last 10 years to capture the most 
recent literature in the area. Protocols for the REA were pre-registered at PROSPERO 
(CRD42018111310, CRD42018111319, CRD42018111349, CRD42018111356, 
CRD42018111357).  
 
For the questions on patients’ experiences and current practice examples, searches of 
grey literature were undertaken in the King’s Fund library and the National Institute for 
Health Research Journals Library. In addition, a call for evidence was issued, asking 
stakeholders to submit evidence informing the responses to those 2 questions 
specifically. A month was allowed for information to be submitted. Details of the call for 
papers request letter can be found in appendix E. 
 
Findings of the REA are summarised in chapter 4. Full reports of the REA are available 
from the NGC via the project web page. 
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Table 2: Methodology per review theme 








Search for SRs and peer 
reviewed publications 
     
Search for grey literature N/A N/A N/A   




the evidence  
Sifting 
process 






























CASP If RCTs / NRS had 
been identified – 
Cochrane would have 
been used. Instead, 
the Institute of Health 
Economics (IHE) 
Quality Appraisal of 
Case Series Studies 











Not possible for 
evidence that was 
retrieved. 
 
SR – systematic review. RCT – Randomised control trials. NRS – Non-randomised studies. RoB – Risk of Bias. ROBINS-I - 
Risk of bias of non-randomized studies of interventions. QUIPS - Quality in Prognosis Studies. CASP - Critical Appraisal Skills 
Programme. GRADE - Grading of Recommendations Assessment, Development and Evaluation. CerQUAL - Confidence in the 
Evidence from Reviews of Qualitative Research. 
 
Other research and reviews 
Using databases of research and reviews other work that had been done in the past, or 
was on the horizon, was also mapped to inform recommendations for further 
investigation. Sources included PROSPERO (the international prospective register of 
systematic reviews), the ISRCTN registry of primary clinical trials, the National Institute 
for Health Research (NIHR), the Integrated Research Application System (IRAS) for 
health & social care and community care research in the UK, and the US National 
Institutes of Health’s ClinicalTrials.gov. 
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3. Prescriptions and prescribing findings 
Prescriptions data from NHS Business Services Authority 
The primary source for this chapter is PHE’s new analysis of dispensed prescriptionsii 
data for adults collected by the NHS Business Services Authority (NHSBSA). 
 
For the NHS payment system in England, NHSBSA requires that data is submitted on 
all prescriptions dispensed in the community. Prescription Cost Analysis (PCA) reports 
are available from the NHS Digital website back to 2004. These reports summarise the 
number of items dispensed and their associated costs. 
 
Since April 2015, NHSBSA has included the patient’s NHS Number within the 
prescriptions dataset. The addition of the NHS Number enables an analysis of the 
number of individuals in receipt of a particular medicine for a particular period, rather 
than counting prescriptions. In addition, the ability to link 2 or more prescriptions for an 
individual means that the duration of continuous prescribing and the co-receipt of 
different types of medicine by the same individual can be estimated.  
 
Aims of the analyses of NHSBSA data 
For each of the 5 medicine classes in the review, the aims of the analysis of NHSBSA 
data are to estimate, for the medicines within the scope of the review: 
 
• the overall prevalence of prescribing to individuals 
• the duration of continuous prescribing to individuals 
• the extent of co-prescribing of drugs between medicine class* 
• the extent of variations in prevalence, duration and co-prescribing over time 
• the extent of such variations by medicine class, gender, age, locality and social 
deprivation 
 
*Co-prescribing of multiple medicines associated with dependence and withdrawal may 
be an issue generally (perhaps increasing the risk of dependence) and specifically 
(particular drug combinations that present risks). Examples include: 
 
• coming off multiple medicines, which may be more difficult, with more complex and 
sequential withdrawal required 
                                            
 
 
ii Throughout this section, references to “prescriptions” and to prescribing are to prescriptions dispensed since only 
these are submitted to NHSBSA for payment and are recorded in the dataset. Some prescriptions are written and 
given to patients but never taken to a pharmacy for dispensing. 
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• the combination of gabapentinoids, opioids and benzodiazepines and z-drugs, which 
can all increase respiratory depression, leading to overdose and possible death95, 97 
• increased risks to the elderly of falls and fractures98, 99 
• the risk of serotonergic syndrome from combining SSRIs and some opioids (like 
tramadol) 100 
 
Analyses have been carried out from national level down to clinical commissioning 
group (CCG) and GP practice level. Summaries of CCG level variation are included in 
this report and data on key indicators by CCG is published in a spreadsheet alongside 
the report. More detailed data at CCG and GP practice levels is not included with the 
report, but is expected to be published by PHE or the NHS. 
 
Exclusions 
The analysis covers all prescribing to patients registered in England, excluding 
prescriptions where: 
 
• no NHS Number is shown (and therefore linkage is not possible)  
• the medicine dispensed was an opioid for the treatment of canceriii  
• the medicine dispensed was for treatment for addictioniv  
• the prescriber was a dentist using the FP10-D form 
 
General caveats and limitations 
Prescriptions are taken to have been dispensed in the month in which NHSBSA 
received the prescription. There may be a delay in submitting the data so this may not 
be equivalent to the month that the prescription was issued or dispensed. It is 
reasonable to assume that there is usually prompt submission of prescriptions so the 
impact on analyses and trends should be minimal, but there will be exceptions to this. 
This limitation has implications for the analysis of duration (see ‘Duration of prescribing’ 
section below). 
 
There was no available method to identify and exclude the following categories of 
prescribing that are outside the scope of the review: (a) prescribing of gabapentin and 
                                            
 
 
iii These opioid prescriptions were identified by matching NHSBSA data to the National Cancer Registration Dataset 
and excluding all opioid prescriptions that were: (a) within 5 years after a diagnosis of cancer; (b) within 6 months 
prior to a diagnosis of cancer; and (c) within one year prior to the date of death, where the cause of death was 
cancer, and the person had a cancer diagnosis at any time. 
 
iv These medicines were identified either by the use of a specific medicine code that indicates use in treatment for 
addiction (via the British National Formulary) and/or use of FP10-MDA (instalment prescribing) form. Principally 
this refers to opioids used in opioid substitution treatment but use of the FP10-MDA can extend to other classes. 
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pregabalin to patients with epilepsyv, and (b) prescribing of opioids for pain in terminal 
illness not identified in the match to the cancer registration dataset. 
 
In a small proportion of cases, there was missing information on a patient’s age or sex, 
so prevalence rates by age groupings or sex may be slightly underestimated. 
 
Data on some prescribing, not intended to be out of scope, may appear in a category to 
which it does not belong. For example, amitriptyline (also used as an antidepressant) is 
recommended for the treatment of pain but is coded only as an antidepressant so 
appears in the data for antidepressants whatever indication it was prescribed for. 
 
Annual data profile 
Overall numbers 
In 2017/18, approximately 11.5 million adultsvi in England received at least one 
prescription for a medicine in one of the 5 classes reviewed (26.3% of the 43.8 million 
resident adults in England). This is defined as the annual prescribing rate. 
 
The number of individuals receiving at least one prescription relevant to the review 
increased slightly from 11.3 million in 2015/16. However, as the resident population also 
increased in this time, the annual prescribing rate was unchanged. 
 
Figure 1 shows the proportion of adults who received a prescription for a medicine in 
each class during 2015 to 2018. The totals for 2017 to 2018 (ranking from largest to 
smallest and rounding to the nearest 100,000) were: 
 
• antidepressants 7.3 million individuals (16.6% of the population) 
• opioid pain medicines (excluding for treatment of cancer pain) 5.6 million (12.8%) 
• gabapentinoids 1.5 million (3.3%) 
• benzodiazepines 1.4 million (3.1%) 
• z-drugs 1.0 million (2.3%) 
 
For consistency, breakdowns by the class of medicine are presented in the above order 
for all cross tabulations. 
 
                                            
 
 
v The vast majority of prescribed gabapentin is coded in prescription data under 'control of epilepsy' (4.8.1) and this 
is what has been used in our analyses. Gabapentin is also coded under 'neuropathic pain' (4.7.3) and this code is 
ostensibly more relevant to the terms of the review. However, so little gabapentin prescribed and dispensed is 
coded as 4.7.3 that it makes almost no difference numerically and it has not been included in the analyses. 
vi This figure excludes those under 18 but includes those where age information was not available (0.6% of cases). 
Only a very small proportion of prescriptions were reported to under 18s, and therefore it is assumed that those 
with missing age information are adults. 
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Figure 1 shows that for antidepressants and gabapentinoids, the prescribing rate 
increased between 2015/2016 and 2017/18. For opioid pain medicines, 
benzodiazepines and z-drugs the prescribing rate decreased. The most marked 
increase was for gabapentinoids, from 2.9% in 2015/16 to 3.3% in 2017/18, or an 
increase of 19% in the number receiving a prescription (from 1.2 million to 1.5 million). 
This reflects the longer-term pattern of increasing prescription numbers described in the 
later section using prescriptions data. 
 
 
Figure 1: Proportion of adults resident in England receiving a prescription 2015 to 
2018, by year and class of medicine 
 
Figure 2 shows the breakdown of all individuals by the first year when they appeared in 
the 3-year reporting period. Between one-half (benzodiazepines) and two-thirds 
(antidepressants) of all those receiving a prescription in any of the 3 years had a 
prescription in the first year of the period (2015 to 2016).  
 
This distribution would be expected given the limited timeframe of the available data. 
Many of those in receipt of a prescription during this period will have been prescribed 
that medicine before 2015 to 2016. 
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Figure 2: Number of adults receiving a prescription 2015 to 2018, by first year 
observed, and class of medicine 
 
Figure 3 shows the breakdown by the number of years (1, 2 or 3) in which individuals 
were observed in the data. Among all adults who received an antidepressant 
prescription at any time in the 3-year periods, the largest group (43%, n=4.4 million) had 
at least one prescription in each of the 3 years. For the other classes of medicine, the 
proportion observed in all 3 years varied between 16% (benzodiazepines) and 31% 
(gabapentinoids).  
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Figure 3: Number of adults receiving a prescription 2015 to 2018, by number of 
years observed, and class of medicine 
 
The receipt of a prescription in each year does not necessarily imply continuous 
prescribing. Similarly, a short prescription around March and April could cross 2 
financial years. Duration of prescribing is analysed in more detail in a later section. 
 
Sex and age group 
Figure 4a shows prescribing rates by medicine class and sex in 2017/18. Across all 
groups, the proportion of women receiving a prescription in the year was at least 1.5 
times higher than the proportion of men. The greatest observed difference by sex was 
for antidepressants, where 21.3% of women received a prescription compared to 11.6% 
of men (1.8 times greater), and the smallest relative difference was for opioid pain 
medicines (15.3% of women, 10.1% of men). 
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Figure 4a: Proportion of adults resident in England receiving a prescription in 
2017 to 2018, by sex and class of medicine 
 
For 2017/18, figure 4b shows for prescribing rates by class and by age group. The 
youngest band is 18 to 24 years. Then, 5-year bands are shown from 25 to 89 years, 
and the oldest group is 90 years and above.  
 
Overall, prescribing rates increased with age, although this was not uniform and there 
were differences between the medicine class. For opioid pain medicines, there was an 
increase with every age group and the oldest age group had around 9 times the 
prescribing rate of the youngest age group. For gabapentinoids, the peak was in the 80-
84 age group, at 12 times higher than the youngest age group, before reducing to 
around 9 times higher in the oldest age group. For antidepressants, the equivalent 
difference was just over 2 times the rate of the oldest to youngest group. 
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Figure 4b: Proportion of adults resident in England receiving a prescription in 
2017 to 2018, by age group and class of medicine 
 
An analysis of prescription rates by age group and sex (not shown here) indicated that 
across every age group, and for each medicine class, the prescribing rates were higher 
among women, while the broad patterns by age group shown in figure 7b were 
observed by sex. 
 
Deprivation 
For the analysis of deprivation, Indices of Multiple Deprivation (IMD) were used, 
grouping GP practices by quintilevii. Each individual was assigned to the deprivation 
quintile associated with their GP practice. Totals by deprivation quintile were summed 
from GP practice totals. 
 
Figure 4c shows the variation in the annual prescribing rate by deprivation. The positive 
(increasing) association between the annual prescribing rate and deprivation quintile 
was pronounced for opioid pain medicines and gabapentinoids. For these medicines, 
the prescribing rate for individuals in the most deprived quintile was approximately 1.6 
times the rate for those in the least deprived quintile.  
 
A less pronounced positive correlation was observed for antidepressants, although the 
most deprived quintile had a markedly increased rate compared to the least deprived 
                                            
 
 
vii For this analysis, the registered population was therefore used as the denominator – the registered population 
exceeds the resident population nationally (46.7 million adults), leading to slightly lower proportions overall. 
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quintile. For benzodiazepines and z-drugs there appeared to be evidence of similar or 




Figure 4c: Proportion of population registered with GPs in England receiving a 
prescription in 2017 to 2018, by deprivation quintile and class of medicine 
 
CCG variations 
For this analysis, rates of the registered population in each CCG were calculated for the 
195 CCGs in England. Crude proportions were first calculated for each CCG to 
compare actual prescribing rates. Age-sex standardised rates were then calculated to 
estimate variations between CCGs having taken into account differences in age-sex 
distribution. 
 
For 2017/18, table 3 shows summary statistics for the 195 CCGs, including the median 
crude proportion receiving a prescription in a CCG, the variation between the lowest 
and highest crude proportions observed in any CCG, and the interquartile range. A 
more detailed analysis of CCG-related data will be published later, after the review. 
 
Table 3: Summary statistics for 195 CCGs in 2017 to 2018 
Medicine class 
Median crude 




a CCG (%) 
Highest 
proportion in 
a CCG (%) 
Interquartile 
range of CCGs 
(%) 
Antidepressants 16.9 7.3 22.5 14.2 - 18.5 
Opioid pain medicines 12.5 5.7 20.6 10.6 - 14.6 
Gabapentinoids 3.2 1.4 6.1 2.5 - 3.9 
Benzodiazepines 2.9 1.2 5.1 2.5 - 3.4 
Z-drugs 2.1 0.9 3.8 1.8 - 2.5 
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Table 4 shows a correlation matrix for the crude proportions receiving a prescription for 
each medicine class by CCG. A crude correlation score between -1 and 1 was assigned 
to compare the proportions in each class. 
 
There were high positive scores between the antidepressant, opioid pain medicine and 
gabapentinoid categories, and between the benzodiazepines and z-drugs categories 
(highlighted in darker green). All other correlations were positive but the relationship for 
other combinations was weaker. This demonstrates that there is a relationship at the 
CCG level between prescribing rates for these classes but does not necessarily mean 
that the same individuals are receiving medicines from more than one of the classes. 
Direct co-prescribing to individuals is explored later in the analysis. 
 
Table 4: Correlation matrix for the crude proportions receiving a prescription for 












Antidepressants - 0.85 0.81 0.51 0.30 
Opioids 0.85 - 0.89 0.32 0.15 
Gabapentinoids 0.81 0.89 - 0.38 0.21 
Benzodiazepines 0.51 0.32 0.38 - 0.80 
Z-drugs 0.30 0.15 0.21 0.80 - 
 
Figure 5 shows the variation in age-sex standardised prescribing rates between CCGs 
across the 5 medicine classes. After age and sex adjustment, there was considerable 
variation between CCGs. There are other factors, such as deprivation, that could 
influence the variation between CCGs and that have not been considered here. 
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Figure 5: Variation in standardised rates by CCG (195 CCGs) and class of 
medicine, 2017 to 2018 
CCGs are ordered from the lowest standardised rate to the highest for each medicine 
class. The order of CCGs therefore varies between the classes. 
 
Duration of prescriptions 
Methodology 
 
Defining duration of prescriptions: 
 
In this analysis, continuous prescribing was estimated by first judging whether an 
individual was in receipt of a prescription in each monthviii. The consecutive months in 
which an individual was judged to be in receipt of a prescription were taken to be 
periods of continuous prescribing. 
 
Retrospective and prospective approaches: 
 
In this analysis, 2 ways of assessing the distribution by duration of prescriptions were 
used. Both provide important information and need to be considered together, but they 
are distinct from one another. They are: 
 
                                            
 
 
viii Depending on the approach taken, it was not always necessary for the individual to have a new prescription 
reported in the month to be judged to be in receipt of a prescription. 
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• Prospective approach – estimates the total number of individuals who started 
a new period of prescribing for a given month and then ‘looks forward’ to the 
duration of continuous prescribing to the end of this period of prescribing, or to 
June 2018 if prescribing is on-going  
• Retrospective approach – estimates the total number of individuals who were 
in receipt of a prescription in a given month, and ‘looks back’ to the duration of 
continuous prescribing up to that point, back to April 2015ix  
 
In the example in table 5, an individual has had 2 prescribing periods (shaded sections), 
each continuously for 4 months. The individual started in month 1 and continued to 
month 4, so their total length of the continuous prescribing was counted as 4 months. If 
reported by the prospective approach at month 1 (highlighted in red), they would be 
reported with a duration of 4 months. For the second period, this began in month 9 and 
the duration of prescribing up until month 12 (the reporting month) was also 4 months 
up until that point, and may or may not continue into month 13 and beyond. If reported 
by the retrospective approach at month 12 (highlighted in blue), they would be reported 
with a duration of 4 months. 
 
When analysing trends, information ‘as at’ the month of reporting is used. Therefore, in 
the example below the individual would be reported by the prospective approach in 
month 9 with a duration of 4 months. They would also appear in the retrospective 
approach in month 11, for example, with a duration of 3 months, as that is the duration 
of the period of prescribing up to that point. 
 
Table 5: Example prescribing pattern for retrospective and prospective analysis 
 
 
Since individuals in receipt of a prescription for a longer duration will go on to appear for 
more months, it would be expected that the retrospective approach will yield higher 
estimates for measures of long-term prescribing in contrast to prospective approach. 
 
Defining current receipt of a prescription: 
 
Three different methods were considered as a way of identifying if an individual is in 
receipt of a prescription at any month and how a period of continuous prescribing is 
defined. These were based on inferences from the observed pattern of prescriptions in 
the NHSBSA data. The inferences were: 
                                            
 
 
ix It is important to appreciate that this includes individuals who started a prescription recently and also those who 
may have been in receipt of one for many years in advance of the reporting period covered by this analysis but 
can only be observed as far back as April 2015. 
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• the defined duration if the individual had to have a new prescription reported in the 
month (so, any month in which no prescription was reported would break off a period 
of continuous prescribing) 
• the defined duration if the individual had no more than one month at any time without 
a prescription reported (for example, if an individual had a prescription reported in 
February and another in April, they would then be judged to have a prescription in 
March) - this method allows for multiple one month breaks within a period of 
continuous prescribing and would include a scenario where prescriptions are 
reported every other month 
• the defined duration if an individual had no more than 2 months at any time without a 
prescription reported - this is the same as the second method but is relaxed to allow 
2 month breaks within a continuous prescribing period 
 
To avoid concurrent reporting of all results by multiple methods, the second method 
(allowing for a one-month gap) was selected as the main approach for the analysis in 
the main body of the report. It was judged that this method had the right balance 
between allowing for genuine reasons for a gap in the data (such as due to 
prescriptions of up to 2 months or delays in reporting to NHSBSA), while reducing the 
risk of considering a prescription to be continuous over what was a real gap in 
prescribing. 
 
However, all methods are compared at a high level in figure 6 (using the retrospective 
approach for March 2018 and measuring those with a continuous duration of 12 months 
or more) so that the difference each approach makes can be seen. Counting 
prescriptions as continuous over one-month breaks (labelled ‘using one month gap’) 
substantially increases the proportion of individuals who are counted as having been in 
receipt of a prescription for 12 months or more across all classes. Counting 
prescriptions as continuous over 2-month breaks (labelled ‘using 2 month gap’) also 
results in a further, smaller increase in this proportion. 
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Figure 6: Proportion with a retrospective duration of greater than or equal to 12 




Any assessment of continuous prescribing from this data will be approximate due to the 
lack of specific information about prescribing dates, which has required inferences to be 
made from the month in which data was submitted to NHSBSA. In particular, it is 
inferred that if an individual is deemed to have a prescription for 2 adjacent months, 
these form part of a continuous prescribing period. Information was not available to 
show how closely together the prescriptions were dispensed, the volume that was 
dispensed or any other information that could help precisely define the length of each 
prescription, so prescriptions may be regarded as continuous where there was a gap in 
prescribing in practice. Conversely, if there is a month in which there was judged not to 
be a prescription, this would close a continuous prescribing period in all circumstances, 
even though it may be that the person did receive a prescription continuously in reality 
(such as an unusual delay in submitting data to NHSBSA). There may also be 
circumstances in which an individual takes the medicine at a different frequency to that 






The data within this section initially reports on individuals who had their first prescription 
of a medicine class in the reporting period submitted during June 2015 and then how 
long they are then continuously prescribed to up to May 2018. A one-month gap has 
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been permitted to allow for prescriptions that last longer than one month and/or to allow 
for delays in prescriptions being submitted to NHSBSA. 
 
Figure 7 shows how many individuals had their first prescription submitted during June 
2015 and how that compares to the total number of individuals who had a prescription 
submitted during 2015 to 2016. For antidepressants, there were around half a million 
people who had their initial prescription in June 2015, compared to 6.8 million people 
overall in the year having a prescription in that class. 
 
 
Figure 7: Number of adults reported as starting a prescription using monthly data 
(June 2015) compared to annual data (2015/16), by drug class
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Prospective duration by class: 
 
The following charts present the continuous prospective length of prescribing for each of 
the medicine classes within the analysis. 
 
 
Figure 8a: Adults starting a prescription for antidepressants in June 2015, by 
prospective duration up to May 2018 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 8a shows the prescribing duration of the approximately 512,000x individuals 
reported as starting a prescription for antidepressants in June 2015. Forty-two per cent 
were only in receipt of a prescription for an antidepressant for one month or less, with a 
further 18% with a duration of 2 or 3 months. The proportion of individuals with longer 
durations then generally decreases until a spike at 36 months, where 7% (around 
33,000) had a continuous prescription for at least the full 36 months from June 2015 to 
May 2018. 
 
                                            
 
 
x Figures in this section are rounded to the nearest 500 
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Figure 8b: Adults starting a prescription for opioid pain medicines in June 2015, 
by prospective duration up to May 2018 
Data for this chart is included in the technical annexe that accompanies the report 
 
In figure 8b, the distribution seen in the antidepressant duration analysis is replicated in 
those starting an opioid prescription in June 2015 (n=498,000) with the majority, 64% 
received a prescription for one month or less, followed by a large drop off to 15% 
receiving a prescription for 2 or 3 months. Proportionally there are then very few people 
receiving prescriptions for each number of months up until 36 months where 3% 
(approximately 16,500) individuals had a prescription lasting for at least the full June 
2015 to May 2018 period. 
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Figure 8c: Adults starting a prescription for gabapentinoids in June 2015, by 
prospective duration up to May 2018 
Data for this chart is included in the technical annexe that accompanies the report 
 
Figure 8c shows the prescribing duration of the 90,000 individuals starting a prescription 
for gabapentinoids in June 2015. Forty-three per cent were only in receipt of a 
prescription for gabapentinoids for one month or less, with a further 18% with a duration 
of 2 or 3 months. The proportion of individuals with longer durations is below 1% for 
each number of months from 13 months until a spike at 36 months, where 8% 
(approximately 7,400) had a continuous prescription for the full 36 months from June 
2015 to May 2018. Note that gabapentinoids may necessarily be prescribed long-term 
to prevent epileptic seizures. 
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Figure 8d: Adults starting a prescription for benzodiazepines in June 2015, by 
prospective duration up to May 2018 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 8d shows the prescribing duration of those starting a prescription for 
benzodiazepines in June 2015 (n=119,000). Seventy-five per cent of people in receipt 
of a prescription for benzodiazepines received it for one month or less, while a further 
12% have a duration of 2 to 3 months. The proportion of individuals with longer 
durations is below 1% for each number of months from 6 months onwards until an 
increase at 36 months, where 2% (around 2,700) had a continuous prescription for the 
full 36 months from June 2015 to May 2018. 
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Figure 8e: Adults starting a prescription for z-drugs in June 2015, by prospective 
duration up to May 2018 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 8e shows the prescribing duration of the 77,000 individuals starting a prescription 
for z-drugs in June 2015. Sixty-eight per cent were only in receipt of a prescription for z-
drugs for one month or less, with a further 14% with a duration of 2 or 3 months. The 
proportion of individuals with longer durations is below 1% from 8 months until 36 
months, where 3% (approximately 2,500) had a continuous prescription for the full 36 
months from June 2015 to May 2018. 
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Comparison of prospective prescribing durations by medicine class 
 
 
Figure 9: Adults starting a prescription in June 2015, by prospective duration 
exceeding thresholds and by medicine class 
 
Figure 9 shows a comparison of different durations of prescribing by medicine class, 
showing the proportions who received a prescription for at least 3 months, at least 6 
months, at least 12 months, at least 24 months or for all months (at least 35 months)xi. 
 
In general, the distribution was very similar across all 5 classes, although the actual 
proportions exceeding the thresholds varied considerably by class. For example, nearly 
half of individuals starting a prescription for antidepressants (49%) and gabapentinoids 




                                            
 
 
xi This includes those who have a prescription for 35 or 36 months, the assumption being that those who only have 
a gap in prescribing in the first month may have been counted in all months if data were available for March 2015. 
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Trend in prospective prescribing 
 
 
Figure 10: Trend in the proportion with a prospective duration of greater than or 
equal to 12 months by medicine class, June 2015 to June 2017 
 
Figure 10 shows the proportion of individuals who were in receipt of a prescription in 
each of the 5 classes continuously for 12 months or more and how this varied over time. 
For all medicine classes this proportion remained relatively stable between June 2015 
and April 2017, with the only percentage point increase in antidepressants at 0.2% and 
the biggest decrease in z-drugs at -1.3%.  
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Figure 11a: Proportion of adults with a prospective duration of greater than or 
equal to 12 months from June 2015, by medicine class and sex 
 
There was little variation in the proportions receiving a prescription for 12 months or 
between men and women, with the largest difference for those starting a prescription in 
June 2015 prescribed gabapentinoids though it was less than 1% (19.4% female vs. 
20.3% male). However, as women have higher prescribing rates generally, the number 
of women receiving a prescription for 12 months or more was greater than the number 
of men in every medicine class. 
 
  





Figure 11b: Proportion of adults with a prospective duration of greater than or 
equal to 12 months from June 2015, by medicine class and age group 
 
In this analysis, age groups are as in the analysis of overall rates, starting at 18 to 24, 
except that here the 90+ age group is split into 90 to 94 and 95+. Generally, the 
proportion of individuals receiving a prescription for 12 months or more increases with 
age, with those on a prescription for antidepressants, z-drugs or benzodiazepines 
showing a reasonably steady linear increase. This proportion for opioid medicines 
increased until around age 50 and then levelled off before increasing again in some 
older age groups, while for gabapentinoids this proportion increased until age 44 before 
stabilising for a period and then increasing notably after age 80. 
 
  





Figure 11c: Proportion of adults with a prospective duration of greater than or 
equal to 12 months from June 2015, by medicine class and deprivation 
 
For opioids, gabapentinoids and benzodiazepines the proportion of individuals receiving 
a prescription for 12 months or more increased with deprivation – with those living in the 
most deprived areas being slightly more likely to be on a prescription for a year or more. 
The most notable difference in this proportion between the most and least deprived 
quintiles was seen in those prescribed gabapentinoids (18% vs 21%). The proportion of 
individuals in receipt of a prescription for 12 months or more by deprivation was stable 
for antidepressants and z-drugs. 
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Variation by CCG:  
 
Table 6 presents the variation at a CCG level in the proportion of individuals receiving a 
prescription for 12 months or more by medicine class, having started at June 2015. 
There are substantial variations between the lowest and highest proportions in a CCG 
across all the medicine classes. 
 
Table 6: Variation at a CCG level in the proportion of individuals receiving a 
prescription for 12 months or more, of those starting a prescription in June 2015, 






a CCG (%) 
Highest 
proportion in 
a CCG (%) 
Interquartile 
range of CCGs 
(%) 
Antidepressants 18.0 7.8 30.6 15.1 - 20.4 
Opioid pain medicines 8.7 4.3 13.8 7.5 - 9.9 
Gabapentinoids 20.3 9.1 31.0 16.7 - 22.1 
Benzodiazepines 5.2 1.6 10.0 4.3 - 6.4 
Z-drugs 7.6 2.2 16.7 6.3 - 9.1 
 
Table 7 shows the correlation in the combinations of medicine classes being prescribed 
for 12 months or more. A correlation score between -1 and 1 is assigned by comparing 
the proportions in each class at CCG level. A higher positive score indicates that CCGs 
that tend to prescribe for 12 months or more for one class of drug also tend to do the 
same for the second medicine class in the combination. 
 
For all combinations there were positive correlations between the proportions 
prescribed to for 12 months or more of the different medicine classes. These 
correlations were much stronger between the antidepressant, opioid and gabapentinoid 
classes, so that CCGs where one of these classes was prescribed at a higher rate for 
12 months or more also tended to have a high rate with another. 
 
Table 7: Correlation between proportions prescribed for 12 months or more at 






Antidepressants Opioid pain medicines Gabapentinoids Benzodiazepines Z-drugs 
Antidepressants - 0.75 0.76 0.40 0.19 
Opioid pain 
medicines 0.75 - 0.74 0.50 0.24 
Gabapentinoids 0.76 0.74 - 0.38 0.17 
Benzodiazepines 0.40 0.50 0.38 - 0.40 
Z-drugs 0.19 0.24 0.17 0.40 - 




Retrospective duration by class: 
 
The data within this section reports on the individuals considered to be in receipt of a 
prescription in March 2018 and how long they had been continuously prescribed that 
class of medicine up until that point in time, back to April 2015. Again, a one-month gap 
was permitted to allow for prescriptions that last longer than one month and/or to allow 
for delays in prescriptions being submitted. 
 
Where an individual is reported to have been in receipt of a prescription for the full 36 
months it is highly likely that they will have already been receiving a prescription for that 
class at the start of the reporting period. It is not possible to determine how long they 
had already been in receipt of prescription at that point as it could range from one 
month to an indefinite period. 
 
Due to the way the data is structured it is likely that a proportion of those in receipt for 
35 months were also in receipt for the full 36 months and already receiving a 
prescription for that class at the start of the reporting period.  
 
Figure 12 shows the number of individuals who have been included in this retrospective 
analysis by having a prescription submitted in March 2018 by class compared to the 
total number receiving a prescription in the year for the same class. Thirty-one per cent 
of those who had a prescription for benzodiazepines during 2017 to 2018 were 
estimated to be in receipt of a prescription in March 2018. This compares to 62% for 
antidepressants.  
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Figure 12: Number of adults reported as receiving a prescription based on using 
monthly data (March 2018) compared to annual data (2017 to 2018)  
 
 
Figure 13a: Adults currently in receipt of a prescription for antidepressants at 
March 2018, by retrospective duration back to April 2015 
Data for this chart is included in the technical annexe that accompanies this report 
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Figure 13a shows the retrospective duration for the 4.48 million individualsxii considered 
to be in receipt of an antidepressant prescription in March 2018. Twenty-one per cent of 
them (approximately 940,000) had been in receipt of a prescription continuously for 
each of the preceding 36 months, with a further 3% (approximately 150,000) having had 
a prescription continuously for 35 months, indicating they were likely to have had a 
continuous prescription for the whole period.  
 
Twelve per cent of individuals (approximately 520,000) had a duration of one month or 
less, denoting that their latest prescribing period began in March 2018. They could have 
had a prescription or prescriptions at other times during the reporting period. 
 




Figure 13b: Adults currently in receipt of a prescription for opioid pain medicines 
at March 2018, by retrospective duration back to April 2015 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 13b shows the retrospective duration for individuals considered to be in receipt of 
a prescription for an opioid pain medicine in March 2018 (n=2.34 million). Of these, 23% 
(approximately 540,000) had been prescribed opioids continuously for 36 months or 
more, with a further 3% (approximately 80,000) who had a continuous prescription for 
35 months. Nineteen per cent had received their first prescription in their latest (or only) 
spell that month.  
                                            
 
 
xii Figures in this section are rounded to the nearest 10,000 




Figure 13c: Adults currently in receipt of a prescription for gabapentinoids at 
March 2018, by retrospective duration back to April 2015 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 13c presents the retrospective duration for individuals considered to be in receipt 
of a prescription for gabapentinoids in March 2018 (n=850,000). Of these, 19% (around 
160,000) had been prescribed gabapentinoids continuously for 36 months or more, with 
a further 3% (around 30,000) who had a continuous prescription for 35 months. Eleven 
per cent (around 100,000) had a prescription duration of one month or less. Note that 
gabapentinoids may necessarily be prescribed long-term to prevent epileptic seizures. 
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Figure 13d: Adults currently in receipt of a prescription for benzodiazepines at 
March 2018, by retrospective duration back to April 2015 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 13d shows the retrospective duration for the individuals with a prescription for 
benzodiazepines reported for them in March 2018 (n=420,000). Of these, 28% 
(approximately 120,000) had been prescribed benzodiazepines continuously for 36 
months or more, with a further 3% (approximately 13,000) who had a continuous 
prescription for 35 months. Twenty-five per cent (approximately 100,000) had a 
prescription duration of one month or less. 
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Figure 13e: Adults currently in receipt of a prescription for z-drugs at March 2018, 
by retrospective duration back to April 2015 
Data for this chart is included in the technical annexe that accompanies this report 
 
Figure 13e shows the retrospective duration for the individuals with a prescription for z-
drugs reported for them in March 2018 (n=360,000). Of these, 28% (approximately 
100,000) had been prescribed z-drugs continuously for 36 months or more, with a 
further 3% (approximately 10,000) who had a continuous prescription for 35 months. 
Twenty per cent (approximately 70,000) had a prescription duration of one month  
or less.  
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Comparison of retrospective prescribing durations by medicine class 
 
 
Figure 14: Adults currently in receipt of a prescription at March 2018, by 
retrospective duration exceeding thresholds by medicine class 
 
The distribution of the duration of prescribing when compared between classes was 
similar, as shown in figure 14, with between 70% and 82% of individuals in all classes 
with a prescription in March 2018 having been in receipt of the prescription for 3 months 
or more. For those receiving a prescription for the full period (35 or 36 months), the 
proportion ranged from 22% (gabapentinoids) to 32% (benzodiazepines). 
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Trend in retrospective prescribing  
 
 
Figure 15: Trend in the proportion with a retrospective duration of greater than or 
equal to 12 months, April 2016 to March 2018 
 
Figure 15 shows the proportion of individuals with a prescription in each of the 5 classes 
in each month that had been in receipt of that prescription continuously for 12 months or 
more and how this proportion varied over time. For all medicine classes this proportion 
has increased by about 5 percentage points between April 2016 and March 2018.  
 
However, this will be in part due to the way the data is structured and that there is a 
‘stock’ of individuals who have a duration of 12 months or more, which is being added to 
as the analysis moves forward month by month. It should therefore be contrasted with 
the prospective trend duration earlier in this report that shows that the proportion of 
people starting a new prescription period in the 3 years who have a duration of greater 
than 12 months has remained relatively stable. 
 
To help understand this difference between the prospective and retrospective analyses, 
the duration was measured using the prospective approach for the cohort who first 
appear in the data in April 2015, following these up to the end of the period. Table 8 
presents the number of individuals in each class who were in receipt of a prescription at 
April 2015 and then received the prescription for the full 36 months up to March 2018. 
For all classes the proportion was around 30%. These proportions were much higher 
than those observed for those commencing a new prescription in June 2015. 
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Table 8: Number and proportion of individuals in each medicine class in receipt 
of a prescription in April 2015 who received a prescription continuously up to 
March 2018 
Medicine class  
Number of 
individuals in receipt 
of prescription April 
2015 (millions, 
rounded to 10,000) 





rounded to 10,000) 
Proportion still in 
receipt of 
prescription (%) 
Antidepressants 3.14 0.93 30 
Opioid pain medicines 1.98 0.54 27 
Gabapentinoids 0.53 0.16 31 
Benzodiazepines 0.40 0.12 29 
Z-drugs 0.33 0.10 31 
 
As these cohorts will include some who genuinely started a new prescribing period in 
April 2015, it is likely that the true proportions of the ‘stock’ already prescribed to at the 
start of the period who were retained for the full period were greater. 
 





Figure 16a: Proportion of adults with a retrospective duration of greater than or 
equal to 12 months at March 2018, by sex 
 
There was little variation in the levels of prescribing over 12 months between men and 
women, with the largest difference at March 2018 seen for those prescribed z-drugs 
though it is only 3% (54.4% female vs. 51.6% male). However, as in the prospective 
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profile, more women were in receipt of prescriptions overall, so greater numbers of 





Figure 16b: Proportion of adults with a retrospective duration of greater than or 
equal to 12 months at March 2018, by age group 
 
Generally, the proportion of individuals receiving a prescription for 12 months or more 
increases with age, with the most consistent increasing pattern seen within those on a 
prescription for antidepressants. The other classes tend to increase quite sharply up 
until about 50 and then level off, apart from gabapentinoids where there was a further 
spike in the oldest age groups.  
 
  





Figure 16c: Proportion of adults with a retrospective duration of greater than or 
equal to 12 months at March 2018, by deprivation 
 
For all medicine classes the proportion of individuals who had been in receipt of a 
prescription for 12 months or more increases in line with deprivation, with those people 
living in the most deprived areas more likely to have been in receipt of a prescription for 
a year or more. The difference in prescribing rates between the most and least deprived 
quintiles was most markedly seen in those prescribed benzodiazepines (57% vs 44%). 
 
Variation by CCG: 
 
Table 9 shows the variation at CCG level in the proportion of individuals who had been 
in receipt of a prescription for 12 months or more by class at March 2018. As with the 
prospective analysis, there were substantial variations between the lowest and highest 
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Table 9: Variation at a CCG level in the proportion of individuals who have been in 





proportion in a 
CCG (%) 
Highest 
proportion in a 
CCG (%) 
Interquartile range 
of CCGs (%) 
Antidepressants 51.7 33.4 65.6 45.9 - 57 
Opioid pain medicines 49.2 32.5 60.7 45.3 - 53.6 
Gabapentinoids 52.9 37.7 63.6 47.7 - 57 
Benzodiazepines 50.0 34.6 68.0 45.2 - 54.9 
Z-drugs 53.6 38.8 68.6 49.1 - 58.2 
 
Table 10 shows the correlations between combinations of classes being prescribed for 
12 months or more. A correlation score between -1 and 1 is assigned by comparing the 
proportions in each class at CCG level. A higher positive score indicates that CCGs who 
tend to prescribe for 12 months or more of one class of drug also prescribe to do the 
same for the second medicine class in the combination.  
 
There were strong correlations between prescribing for 12 months or more of different 
combinations of classes, with particularly strong correlations between the 
antidepressant, opioid and gabapentinoid classes. This means that, where larger 
proportions have been in receipt of prescriptions for 12 months or more in one of these 
classes, this also tends to be the case for the other classes. 
 
Table 10: Correlation between proportions that have been in receipt of a 
prescription for 12 months or more at CCG level, by drug class, March 2018 
Medicine classes 
being compared Antidepressants 
Opioid pain 
medicines Gabapentinoids Benzodiazepines Z-drugs 
Antidepressants - 0.86 0.91 0.71 0.72 
Opioid pain 
medicines 0.86 - 0.90 0.79 0.74 
Gabapentinoids 0.91 0.90 - 0.76 0.71 
Benzodiazepines 0.71 0.79 0.76 - 0.77 
Z-drugs 0.72 0.74 0.71 0.77 - 
 
In addition, table 11 shows correlation scores for overall prescribing rates at CCG level 
compared to the proportions who have been in receipt of a prescription for 12 months or 
more. This shows that, for antidepressants, opioids and gabapentinoids, there were 
strong relationships between CCGs that prescribed at higher rates and those that more 
commonly prescribed the same class of medicine for 12 months or more. For 
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Table 11: Correlation between proportions that have been in receipt of a 
prescription for 12 months or more and overall prescribing rates at CCG level, by 
drug class, March 2018 
Comparison Antidepressants 
Opioid pain 
medicines Gabapentinoids Benzodiazepines Z-drugs 
Proportion with a 
retrospective 
duration of 12 
months or more 
compared to 
overall prescribing 
rate in CCG 
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Co-prescribing between classes 
Defining co-prescribing 
In this analysis, co-prescribing refers to the reporting of 2 or more classes of medicine 
for the same person in the same month. As elsewhere in the analyses, this is based on 
the month in which prescriptions were submitted for payment. It is therefore assumed 
that any delays in submission of prescriptions to BSA are similar across the classes. 
 
For most of this analysis, co-prescribing is reported based on the number of classes (up 
to 5) that were reported in the same month, with >=2 deemed to be co-prescribing. A 
high-level breakdown of the specific combinations is reported nationally. 
 
Limitations 
The main limitation is that it is not possible to distinguish whether multiple prescriptions 
have been reported for the same month are given consecutively or concurrently. As 
such, some activity will be flagged in this analysis as co-prescribing (implying 
concurrent receipt) when in fact the individual was prescribed one medicine and then 
separately the other, where both were reported in the same month. 
 
To address this, a sensitivity analysis was produced which only counted an individual as 
receiving a co-prescription if the combination of classes of medicine was observed for 







In total, 5.5 million individuals received a prescription in March 2018 in at least one of 
the classes. Figure 20 shows the breakdown by the number of classes of medicine an 
individual received in that month. Three-quarters (75%) were receiving a prescription in 
one class only, while the remaining one-quarter (25%) were receiving prescriptions in 2 
or more classes (so were considered to be co-prescribed to within these classes of 
medicine). This is taken to be the co-prescribing rate. Of these, the large majority (19% 
of all those with a prescription in March 2018) were receiving prescriptions in 2 different 
classes, with most of the rest (5%) receiving prescriptions in 3 classes. 
 
Prescribed medicines: an evidence review 
81 
 
Figure 17: Proportion of adults receiving a prescription in March 2018, by number 
of classes of drug 
 
Sex and age variation: 
 
Figure 18 shows the difference in the distribution by the number of classes and by sex. 
Overall, women receiving a prescription in March 2018 had a slightly higher co-
prescribing rate compared to men in the same month (26% vs. 24%). 
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Figure 18: Proportion of adults receiving a prescription in March 2018, by sex and 




Figure 19 shows the breakdown by the number of classes according to age group. 
While overall prescribing and duration of prescribing tends to increase with age into the 
oldest age groups, the co-prescribing rate increased up to a peak in the 55-59 age 
group (30%), after which the proportions decreased with age up to the 95+ age group 
(23%). 
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Figure 19: Proportion of adults receiving a prescription in March 2018, by age 




Figure 20 shows the breakdown by the number of classes according by deprivation 
quintile. There is a clear relationship between increasing deprivation and increasing co-
prescribing rates, with the co-prescribing rate in the most deprived quintile 1.4 times 
higher than in the least deprived quintile (30% compared to 21%). 
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Figure 20: Proportion of adults receiving a prescription in March 2018, by 
deprivation and number of medicine classes 
 
Combinations of co-prescription: 
 
Table 12 shows the number of individuals who received each combination of 2 or more 
classes of medicine in March 2018, grouped by the number of classes, and the 
proportion of the total (n=5.5 million) that this represents. A combination refers to the 
classes that were prescribed in the individual month and, by implication, means other 
classes were not. For example, “antidepressants, opioids and gabapentinoids” means 
that the individual did not receive benzodiazepines or z-drugs at that point in time, 
though they might have done in another month during the 3 years. 
 
The most common pairing was antidepressants and opioids, with 9% receiving these 2 
classes alone and 14% receiving a combination which included both these classes and 
up to 3 other classes. The most common combination of 3 classes was antidepressants, 
opioids and gabapentinoids, with 3% receiving these 3 classes alone and 4% receiving 
a combination which included these drugs. 
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Table 12: Number of individuals receiving each combination of 2 or more classes 
of medicine in March 2018, grouped by the number of classes, and the proportion 
















19.1 Antidepressants and opioids 513 9.3 
Antidepressants and gabapentinoids 162 2.9 
Gabapentinoids and opioids 116.6 2.1 
Antidepressants and benzodiazepines 90.1 1.6 
Antidepressants and z-drugs 81.3 1.5 
Benzodiazepines and opioids 39.8 0.7 
Opioids and z-drugs 25.2 0.5 
Benzodiazepines and z-drugs 8.1 0.1 
Benzodiazepines and gabapentinoids 7 0.1 
Gabapentinoids and z-drugs 5.8 0.1 
Three 
classes 
5.2 Antidepressants, gabapentinoids and opioids 156.7 2.8 
Antidepressants, benzodiazepines and 
opioids 
42.9 0.8 
Antidepressants, opioids and z-drugs 32.9 0.6 
Antidepressants, benzodiazepines and z-
drugs 
13.6 0.2 
Antidepressants, benzodiazepines and 
gabapentinoids 
12.7 0.2 
Antidepressants, gabapentinoids and z-drugs 10.6 0.2 
Benzodiazepines, gabapentinoids and 
opioids 
6.7 0.1 
Gabapentinoids, opioids and z-drugs 4.6 0.1 
Benzodiazepines, opioids and z-drugs 3.1 0.1 





0.8 Antidepressants, benzodiazepines, 
gabapentinoids and opioids 
18.4 0.3 
Antidepressants, gabapentinoids, opioids 
and z-drugs 
13.4 0.2 




gabapentinoids and z-drugs 
3 0.1 





0.1 Antidepressants, benzodiazepines, 
gabapentinoids, opioids and z-drugs 
4.5 0.1 
 
Figure 21 shows the numbers of individuals who received each co-prescribing 
combination from the table above, grouped by the number of classes. For brevity, the 
combinations are summarised in this graph with abbreviated codes where the first letter 
of each relevant medicine class is shown. For example, “AO” refers to “antidepressants 
and opioids”. 
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Figure 21: Number of adults receiving a prescription in March 2018, by 
combination of classes 
For example, “AO” indicates antidepressant and opioid 
 
Variation by CCG: 
 
Table 13 shows the extent of variation between CCGs in the proportion of individuals 
where more than or equal to=2 classes were reported for an individual at March 2018. 
This shows that half of CCGs had a co-prescribing rate within the range of 23% to 
26.5%, close to the median of 25%. 
 
Table 13: Summary statistics for those with 2 or more classes of medicine 
reported in the same month at CCG level  
Median proportion (%) Lowest proportion in a CCG (%) 
Highest proportion in a 
CCG (%) 
Interquartile range of 
CCGs (%) 




As noted above in the Limitations section, the key limitation of this analysis of co-
prescribing is that prescriptions from multiple classes reported against the same month 
may reflect a transition from one drug to another rather than a co-prescription. To test 
this, a sensitivity analysis was carried out introducing a further rule to only report co-
prescribing where the combination of drugs was reported for consecutive months and 
would therefore very likely reflect concurrent prescriptions. 
 
Figure 22 shows the high-level results of this analysis for March 2018. With the 
additional rule that combination of drugs must also be identified in February or April 
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2018, the co-prescribing rate at this time would be 19%, compared to the 25% shown in 
Figure 20. It should be noted that this method is quite conservative and may disregard 
cases of genuine co-prescribing, where that combination of classes was only observed 
in one month. It would be reasonable to suggest that the true rate of co-prescription at 
any time is probably between one-fifth and one-quarter. 
 
 
Figure 22: Proportion of adults receiving a prescription in March 2018, by number 
of medicine classes – based on sensitivity analysis method 
 
Earlier prescription data 
As the individual patient-level NHSBSA prescription data only covers 2015 to 2018, 
published prescription data going further back (to 2008) was also examined to provide a 
longer-term trend in prescription volumes. This is contained in the NHSBSA’s annual 
Prescription Cost Analysis (PCA) reports101 and in its latest trend report.102 What this 
data cannot do is cover duration of prescribing or numbers of individuals prescribed to. 
This prescription data is available going even further back than 2008 but data for the 
years 1991 to 2009 on prescriptions for some medicines liable to “addiction” was 
included in a 2011 report by the National Treatment Agency103 (although this did not 
include antidepressants or gabapentinoids) and can be attached to the data that follows 
to give even longer trends. But these trends largely reflect the patterns seen in the last 
10 years, just starting from a lower base. 
Longer-term prescription trend data echoes the more recent patterns shown in the BSA 
analysis: 
 
• antidepressant prescriptions being by far the largest in number and doubling over 10 
years 
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• opioid analgesic prescriptions (including opioid compound analgesics) having 
increased to 2016 before starting to fall 
• benzodiazepines being the only class of medicines in the scope of the review whose 
prescriptions have consistently decreased  
• z-drug prescription numbers having remained fairly flat over the period, increasing a 
little and then falling again 
• gabapentinoid prescriptions being much smaller in number but having shown by far 
the greatest proportional increase, more than quadrupling in 10 years 
 
Note: These figures in figure 23 below are raw prescription item numbers and have not 
been adjusted for the population, which has also been increasing and will mean any 
relative rates of increase have been less than shown. 
 
 
Figure 23: Prescription items dispensed in the community in England, 2008 to 
2018 
Source: NHSBSA PCA. Opioids includes the opioid compound analgesics, co-codamol and co-dydramol 
 
Breaking down the antidepressant prescriptions into the different types (figure 24) 
shows how the use of monoamine oxidase inhibitors (MAOIs) has remained very small, 
tricyclics have remained fairly stable, and the total increase is mostly explained by 











2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Prescription items dispensed in the community in England, 2008-18
Antidepressants Opioids Gabapentinoids
Z-drugs Benzodiazepines
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Figure 24: Prescription items 2008 to 2018, antidepressants-only, by class 
Source: NHSBSA PCA 
 
Prescribing privately and in other settings 
To complement the NHSBSA prescription data, which only covers NHS prescriptions 
dispensed in the community, PHE obtained data from IQVIA that covered: 
 
• hospitals – medicines dispensed from NHS hospital pharmacies for 5 years, 
November 2013 to October 2018 
• care homes – prescriptions dispensed for residents in care homes in England for 2 
years, November 2016 to October 2018 (unlike the prescribing data in the other 2 
additional datasets, these prescriptions are reflected in NHSBSA prescription data – 
they are presented here because of interest in prescribing in care homes) 
• private prescriptions – private prescriptions dispensed from retail pharmacists in 
England for 2 years, November 2016 to October 2018 
 
This additional data further supplements the findings from the other analyses. Although 
it only provides counts of items or quantities, and cannot be analysed by patient, it 
provides further evidence of volume of, and recent trends in, prescribing. In terms of 
volume, antidepressants dominate prescribing in all settings except hospitals, which 
give out far more opioids than the other medicine classes. This might be as expected 
since a much higher proportion of people being prescribed for by hospitals will be in 
pain following an accident or surgical procedure or similar. However, hospitals are also 











2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Prescription items 2008-2018, antidepressants-only, by class
SSRIs Tricyclics Other MAOIs
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The volume of prescriptions varies considerably between the settings and the difference 
in these volumes should be borne in mind when interpreting the data. Data for private 
prescriptions in particular may be more variable due to the relatively very low volume 
compared to other settings. For example, in October 2018, the number of units of 
antidepressants dispensed in the community was almost 10,000 times greater than the 
number dispensed via private prescriptions. 
 
In terms of trends in prescribing over the period covered by the data, these are largely 
consistent between all the settings. Apparently significant differences are: 
 
• prescribing of z-drugs has fallen more in care homes than in other settings 
• private prescriptions for opioids decreased from October 2017 to April 2018 but then 




• community data from PCA (figure 25) is essentially the same data as in 
figure 23 but divided into quarters, and only for November 2016 to 
October 2018, to allow comparison with the other IQVIA-supplied data 
• monthly data has been aggregated to quarters to smooth out random 
fluctuations 
• data is only presented for the 2 years covered by all IQVIA-supplied 
data 








Figure 25: IQVIA - Drug group analysis - community (items dispensed) 




Figure 26: IQVIA - Drug group analysis – hospitals (units) 
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Figure 27: IQVIA - Drug group analysis – care homes (units) 




Figure 28: IQVIA - Drug group analysis – private prescriptions (units) 
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Clinical Practice Research Datalink 
A parallel study by the Public Health Research Consortium (PHRC), updating and 
expanding on research on dependence forming medicinesxiii (DFM) published in 2017,2 
has provided findings on prescription length and prescribing duration from the Clinical 
Practice Research Datalink (CPRD) that go further back than the NHSBSA prescription 
data.104 A separate analysis has been added to include antidepressants (ADM).105 
These show that: 
 
"A downward trend has been evident for benzodiazepines and - since 2004 - for 
GABAergic medicines in the proportion of individual prescriptions to exceed 30 days. 
The rate has been more stable for opioids and Z drugs." 
 
"When the  2 main GABAergic medicines were examined separately, we can see that 
the overall fall in 2004 in the proportion of prescriptions exceeding 30 days was due to 
the introduction of pregabalin in that year. The proportion of pregabalin prescriptions to 
exceed 30 days has remained about half the rate for gabapentin. Trends for GABAergic 
medicines as a whole are likely to reflect changes in how much of the total prescribing 
was for pregabalin and how much was for gabapentin." 
 
“A minority of individual ADM prescriptions exceed 60 days: this was consistently more 
likely for tricyclics (2% to 4%) than for SSRIs or other ADMs (both consistently below 
2%). The proportion of tricyclic and other ADM individual prescriptions to exceed 60 
days fluctuated, but with a general downward trend over time. For SSRIs, the proportion 
of individual prescriptions to exceed 60 days remained stable over time.” 
 
In terms of continuous prescribing periods the CPRD analysis found: 
 
Benzodiazepines 
“While there has been a steep fall in the proportion of benzodiazepine prescribing 
periods to exceed 30 days (from about half of prescribing periods in 2000 to a third in 
2014), reductions in the proportions of prescribing periods to exceed 6 and 12 months 
have been less clear. 
 
In 2014, 12% of continuous benzodiazepine prescribing periods exceeded 6 months. 
Half of these (6% of prescribing periods that year) exceeded 12 months. There are 
indications of a slight downward trend over time. Around 13% of prescribing periods 
exceeded 6 months in 2001 to 2003, while since 2007 10% to 12% were prescribed at 
this level.” 
                                            
 
 
xiii Benzodiazepines, z-drugs, opioids and GABAergic medicines 




“In 2014, 37% of continuous Z drug prescribing periods exceeded 30 days. The rate has 
had a slight downward trend over time. Similar to benzodiazepines, in 2014 13% of Z 
drug continuous prescribing periods exceeded 6 months, and 6% exceeded a year. 
While the rate exceeding 30 days appears to have decreased, the rate exceeding these 
longer thresholds may be increasing.” 
 
Opioids 
“Similarly, while the proportion of continuous prescribing periods to exceed 30 days 
reduced (from 38% in 2001 to 34% in 2014) no reduction was evident at the longer 
thresholds. Rather, the data was indicative of a slight upward trend over time.” 
 
Gabapentin 
“Since 2010, the proportion of gabapentin prescribing periods to exceed 30 days fell 
from 76% to 60% in 2014. The rates exceeding 6 and 12 months fluctuate in the data 
but are not consistent with a pattern of long-time decline.” 
 
Pregabalin 
“While the proportion of pregabalin prescribing periods to exceed 30 days remained 
around 60% between 2004 and 2014, the proportion to exceed longer thresholds 
steadily grew over this period. In 2014, 16% of continuous pregabalin prescribing 
periods exceed 6 months and 8% exceeded a year.” 
 
Antidepressants 
“The mean average number of days of SSRI, tricyclic, and other ADM continuous 
prescribing periods increased year on year between 2005 and 2011.” 
 
“For each type of ADM, the proportion of continuous prescribing periods to exceed one 
year increased between 2001 and 2011/2. Since 2012 there is evidence of a possible 
decline in the proportion of continuous prescribing periods to exceed this threshold.” 
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Characteristics of people prescribed DFM and antidepressants long-term 
PHRC also examined the characteristics of people prescribed DFM medicines long-term 
and, like the analysis in this report, found: 
 
• for most types of DFM (except opioids), older people prescribed the drug were more 
likely than younger people to be prescribed it for more than 6 months - for example, 
in 2014 18.7% of those aged 81 and over who were prescribed z-drugs were 
prescribed to for more than 6 months, compared with 5.1% of those prescribed the 
drug who were 18 to 40-year olds 
• in 2014, for all types of DFM, continuous prescribing periods in excess of 12 months 
were slightly more likely among men prescribed the drug than among women - 
differences by sex, however, were not evident at other prescribing thresholds or in 
earlier years  
• people prescribed DFM and living in the North of England were more likely than 
those living in other regions to be prescribed to for periods more than 6 and 12 
months - this was the case for all classes of DFM 
• among people prescribed DFM, those living in deprived areas were generally more 
likely to be prescribed to for longer - this association, for example, has remained 
evident and pronounced among those prescribed opioids in every year of the data 
extract 
 
For antidepressants, PHRC found: 
 
• men prescribed SSRIs were more likely than women to be prescribed them for 
longer than 3 years - there was little variation by gender of prescribing duration of 
tricyclics; for other ADM, after 2008 men were more likely to be prescribed to long-
term 
• older people prescribed SSRIs were more likely than younger people to be 
prescribed to for more than 3 years - among people prescribed tricyclics and other 
ADMs, associations with age were less clear 
• SSRIs and tricyclics were also more likely to be prescribed long-term in the North of 
England 
 
PHRC’s conclusions and implications 
“Prescribing periods average about a year: Since 2000, individual prescriptions have 
been issued for short periods of time - overwhelmingly for less than 60 days.  
Continuous prescribing periods, however, last much longer. In 2011, the average SSRI 
prescribing period was just under a year, and the average tricyclic or other ADM 
prescribing period lasted well over a year.  
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“Average prescribing periods have gradually increased over time: The rise in mean 
number of days was less pronounced for SSRI and more pronounced for other ADM.  
 
“One in 12 tricyclic and other ADM prescribing periods exceed 3 years: 
The proportion of SSRI prescribing periods to exceed 3 years remained around 4% 
between 2003 and 2014, while the proportion of ADM prescribing periods to exceed this 
length doubled between 2003 (4%) and 2014 (8%). 
 
“There are indications that in recent years the proportion of prescribing periods to 
exceed long thresholds has fallen. This could result from changes such as greater 
switching between types of ADM.  
 
“Variation among those prescribed to: Those more likely to be prescribed ADM beyond 
a 3-year threshold tended to be older, male, and living in the North of England – 
although this pattern varied by type of drug.” 
 
Over-the-counter medicines 
Finally, PHRC’s research looked at data from IRI on sales of codeine and 
dihydrocodeine-containing medicines bought over-the-counter (OTC) from February 
2015 to February 2018. Total counts of individual tablets were derived for each 12-
month period from week ending 28 February, 2015. Counts were calculated from the 
sales volume multiplied by the pack size. 
 
 
Figure 29: Total counts of sales of individual codeine and dihydrocodeine-
containing medicines 
Source: IRI Group Ltd data on sales of OTC products (including own-label and generic) from all multiples and independent 
pharmacies and most supermarkets and grocery outlets in Great Britain. Independent grocers were generally not included in 
the sales data, which means that trends over time are likely to be reliable but the total volume is an underestimate 
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PHRC’s analysis says: 
 
“There was a small decrease in total OTC sales of medicines containing codeine or 
dihydrocodeine between 2015/2016 and 2017/2018, broadly consistent across 
categories. Apart from a small increase over time in sales of ibuprofen and codeine 
combinations (1% increase), all types of medicine showed small decreases in sales 
volume between 2015/6 and 2017/18. The largest drop in sales was in aspirin and 
codeine products (15% reduction). 
 
“These trends are broadly consistent with those reported for all analgesics in The 
Pharmaceutical Journal using sales data supplied by IRI Ltd (Connelly, 2017), as well 
as by Nielsen Scantrack (Connelly, 2018). The more recent article described sales of 




“Connelly D. A breakdown of the over-the-counter medicines market in Britain in 2016. 
The Pharmaceutical Journal, April 2017, Vol 298, No 7900, online | DOI: 
10.1211/PJ.2017.20202662.  
 
“Connelly D. A breakdown of the over-the-counter medicines market in Britain in 2017. 
The Pharmaceutical Journal, May 2018, Vol 300, No 7913” 
 
Other data and analyses 
PHE will explore future opportunities to provide NHS cost estimates derived from the 
review data. 
 
ONS publishes annual data on drug poisonings, including from medicines in the scope 
of this review. This data is not repeated here, but PHE plans to analyse death rates 
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4. Rapid evidence assessment findings  
The findings in the following sections are based on the rapid evidence assessment 
(REA) described in chapter 2. As noted earlier, the REA was limited to 10 years  
(1 January 2008 to 3 October 2018).  
 
The NGC identified 39,087 records through database searches and 249 records were 
identified through other sources. After screening and record exclusion, 1,067 text 
articles were assessed for eligibility. A total of 75 articles were included from the 
literature searches: 30 on harms, 26 on interventions, 17 on risk factors, and 2 on 
patients’ experiences. From the open call-for-evidence, 10 additional reports on 
patients’ experiences were included along with 4 reports on current practice. 
 
 
Figure 30: Study selection: Flow chart of study selection for the review 
  
Records screened, n=39336 
Records excluded, n=38269 
(113 requested but unobtainable) 
Papers included in review: 
•Harms   n=30 
•Risk factors    n=17 
• Interventions  n=28 
•Patients’ experience n=2 
(10 additional identified from call for 
evidence, leading to 12 total) 
•Current practice  n=0  
(3 included identified from call for 
evidence, 1 from grey literature, 
leading to 4 total) 
Papers excluded from full text sift, 
n=990 
 
Reasons for exclusion are in an 
appendix in the full REA reports 
Records identified through database 
searching, n=39087 
Additional records identified through 
other sources, n=249  
Full-text papers assessed for eligibility, 
n=1067 
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Risk of harms of dependence and withdrawal 
The question addressed in the rapid evidence assessment in relation to risk of harms of 
dependence and withdrawal was: 
 
“What are the factors that contribute to the risk of harms associated with dependence 
and the short term discontinuation or longer term withdrawal symptoms from the 
following prescribed medicines: opioids for chronic pain (excluding end of life/palliative 
care/cancer pain), benzodiazepines, z-drugs, gabapentin and pregabalin (excluding 
epilepsy treatment), and antidepressants?” 
 
Conclusions drawn from the evidence identified were: 
 
“A wide range of potential risk factors for harms of dependency were identified from the 
literature, however, all of the available evidence was relating to use of opioids or 
benzodiazepines. No evidence that was relevant to the review protocol was available for 
antidepressant withdrawals, z-drugs or gabapentinoids. 
 
“There was considerable variation in methods to define the risk factors and a variety of 
methods to measure dependence, mean combining these data were not possible. 
Furthermore, the studies differed in terms of potential confounding factors that they had 
adjusted for, and in some cases the detail regarding the specific factors that were 
adjusted for wasn’t clearly reported. This taken alongside risk of bias in the studies and 
uncertainty in the effect resulted in all the evidence being graded as low or very low 
quality. Some results are conflicting between studies and firm conclusions can’t be 
made from this evidence alone. Nonetheless it does provide information on potential 
risk factors to be considered in relation to dependence or long term use. 
 
“Factors identified from this literature that appear to demonstrate the strongest effect: 
 
Opioids 
• High initial dose – this was observed as a risk factor for long-term use of opioids 
from 2 studies, using different referents (<900mg and <250mg) and a dose-response 
gradient was suggested. It should be noted that the larger study was not adjusted for 
pain severity 
• Pain intensity – one study reported that pain intensity at baseline rated at 5-6 or 8-
10, on a 0-10 scale (where zero = ‘no pain’ to ‘pain as bad as could be’) was a risk 
factor for receiving a diagnosis of dependence. It should be noted that this was not 
adjusted for opioid dose 
• Duration of treatment greater than 90 days – one study suggested this as a possible 
risk for opioid overdose and opioid dependence (but also for risk of dependence to 
other substances and depression) 
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• Prior or concurrent use of benzodiazepines, NSAIDs or pregabalin – effects varied in 
magnitude but one large, well-conducted study, suggested that this may be a risk 
factor long-term opioid use.  
• The majority of the evidence (5 out of 6 studies), some of large sample size, 
suggested a mental health diagnosis as a possible risk factor for dependence 
(defined as official diagnosis, early opioid refills or persistent use). However, the size 
of this effect varied as did how the prognostic factor and outcome were defined. 
 
Benzodiazepines 
• Ethnicity – 2 studies identified non-white ethnicity (Black, Latino, or Asian; and 
Chinese or South Asian) being at lower risk of benzodiazepine dependence 
diagnosis or chronic sedative use compared to people of white ethnicity. The 
possible mechanisms underlying this effect, such as clinician perceptions and 
prescribing practices, should be considered 
• Income – one study with a large sample size reported a modest effect size but clear 
gradient of increasing risk with decreasing income compared with the highest 
population income quintile  
• Number and type of benzodiazepine prescribed – being prescribed 2 or 3 or more 
different benzodiazepines compared to one, and being prescribed a short-acting 
benzodiazepine compared with a long-acting one, were both reported as risk factors 
for long-term use in one study with a large sample size 
 
“The other positive results were derived from studies with either modest effect sizes, 
single studies of small sample size or not consistent between studies and so it was 
difficult to draw conclusions from these data. 
 
“As highlighted, all these conclusions should be interpreted with caution due to the low 
or very low quality of the evidence informing the conclusions, primarily due to risk of 
bias. Further research into the risk factors listed above that appear most likely to be 
associated from the evidence reviewed would be of value to strengthen this evidence 
base. Good quality research in this area is particularly lacking in other drugs of interest 
within this rapid evidence assessment. The variation in potential risk factors observed 
for opioids and benzodiazepines suggests that extrapolation of this preliminary findings 
should not be made to other medicine classes without further research in the area.” 
 
Harms associated with or caused by dependence and withdrawal 
The question addressed in the rapid evidence assessment in relation to harms was: 
 
“What are the harms associated with dependence, and the short term discontinuation 
and longer term withdrawal symptoms from the following prescribed medicines: opioids 
for chronic pain (excluding end of life /palliative care/cancer pain), benzodiazepines,  
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z-drugs, gabapentin and pregabalin (excluding epilepsy treatment), and 
antidepressants?” 
 
Conclusions drawn from the evidence identified were: 
 
“There is a lack of good quality quantitative evidence of the harms of dependency of the 
prescription medications included in this review. The only available evidence informing 
this area was comparing 2 different opioids and indicated that oxycodone may be more 
harmful than tapentadol in developing doctor shopping behaviour. Another study 
suggested that longer term use of opioids led to more incidences of depression, alcohol 
abuse, opioid abuse, other substance abuse, opioid overdose, other substance 
overdose, opioid dependence and other substance dependence. It is unclear whether 
these are due to dependence on the opioid however, as long term use was used as a 
proxy for dependence. 
 
“Good quality recent evidence was lacking for benzodiazepines for all areas covered in 
the review. All this evidence was considered low to very low quality, meaning firm 
conclusions cannot be drawn from the effects observed and it is likely that more 
evidence would change the conclusions drawn from this. Similarly, there was only one 
study identified for z-drugs. This very limited recent evidence base for these drugs is 
insufficient for drawing conclusions. 
 
“Whether or not a gradual tapering schedule minimised the adverse effects experiences 
was inconclusive from this evidence, although there did appear to be some advantage 
compared to abruptly stopping the medication. 
 
“The majority of the available evidence was for harms from withdrawal or 
discontinuation of these medications. Most of these were from pharmaceutical funded 
trials designed to look at efficacy of medications rather than withdrawal from the drugs. 
However, from these trials there was a clear suggestion that when compared to 
placebo, withdrawal from antidepressants may lead to more people experiencing 
withdrawal syndrome, including taper/post-study emergent adverse events such as 
vertigo, dizziness and nausea. 
 
“Further research would be beneficial to increase confidence in the findings from this 
review and to further clarify the harms experienced in withdrawing/discontinuing from 
long term opioid use and antidepressants, including longer term outcomes for all groups 
of drugs included.” 
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Prevention and treatment 
The question addressed in the rapid evidence assessment in relation to prevention and 
treatment was: 
 
“What are the most effective and cost effective approaches to the prevention and 
treatment of dependence and the short term discontinuation or longer term withdrawal 
symptoms from the following prescribed medicines: opioids for chronic pain (excluding 
end of life/palliative care/cancer pain), benzodiazepines, z-drugs, gabapentin and 
pregabalin (excluding epilepsy treatment), and antidepressants?” 
 
Conclusions drawn from the evidence identified were: 
 
"The majority of the evidence identified was for interventions for the prevention and 
treatment of dependence and the short term discontinuation or longer term withdrawal 
symptoms from opioids or benzodiazepines, with less evidence identified for 
antidepressants and Z-drugs and no evidence identified for gabapentinoids.  
 
“All of the included studies compared interventions with usual care, different types of the 
same approach with each other or were non-comparative. There were no direct 
comparisons between different approaches.  
 
“Variation between studies in the interventions and comparators meant that meta-
analysis was not possible.  
 
“Several outcomes were downgraded for indirectness because the studies included an 
indirect population. This was most often because the specific drugs used were not 
reported; therefore, it is uncertain whether the evidence is applicable to the review 
population. 
 
“The quality of the evidence ranged from moderate to very low, with the majority of the 
outcomes being of very low quality. This was due to risk of bias, indirectness and 
imprecision. 
 
“Considering the significant limitations of the evidence, no firm conclusions can be 
drawn regarding the most effective approach to the prevention and treatment of 
dependence and the short term discontinuation or longer term withdrawal symptoms 
from prescribed medicines, although there does appear to be some weak evidence of 
benefit for patient education or support programmes, although this is inconsistently 
observed.” 
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To gain a broader picture of the harms perceived by patients, the review was 
supplemented by a call for more experiential evidence, which was included in the 
questions that follow. 
 
Patients’ experiences of harms and of accessing support 
The question addressed in the rapid evidence assessment in relation to patients’ 
experiences was: 
 
“What is the current evidence about patients’ own experiences of the harms caused by 
prescribed medicines specifically relating to dependence and the short term 
discontinuation or longer term withdrawal symptoms from the following prescribed 
medicines: opioids for chronic pain (excluding end of life /palliative care/cancer pain), 
benzodiazepines, z-drugs, gabapentin and pregabalin (excluding epilepsy treatment), 
and antidepressants, and experiences of accessing and engaging in treatment?” 
 
To ensure findings were relevant to the experiences of patients using the NHS (being 
prescribed, treated and accessing support), only studies or reports conducted in the UK 
were included in this part of the literature review. The time frame used was 2008 to 
2018, and papers did not have to appear in peer-reviewed journals but did have to be 
publicly available, for example on an organisational website or in a publicly available 
annual report. 
 
As a result of the call for papers and database literature search 12 papers in total were 
included in the review looking at patients’ experiences. References are all in the REA 
report on patient experiences. Of these, 3 papers were qualitative studies, 3 were 
reports, one a Health Technology Appraisal (HTA), and the remaining 5 were based on 
online information on patient experiences. All papers covered prescribed 
antidepressants, with 2 papers also focusing on benzodiazepines, opioids and z-drugs. 
No papers were identified for patients’ experiences of the use of gabapentin and 
pregabalin. 
 
The main findings are based on overarching themes across the 3 types of evidence: 
qualitative studies, reports and papers based on online information. All examples shown 
are from findings with a ‘high’ or ‘moderate’ confidence rating. 
 
Finding 1. Patients experience physical, emotional, social and sexual side effects with 
benzodiazepines, z-drugs, opioids and antidepressants  
Participants described physical and emotional side effects of antidepressant use in 
particular. Some participants felt that the treatment was often worse than the illness. 
They felt that, especially with antidepressants and benzodiazepines, there was an 
overall negative impact on their lives including impact on relationships and social life, 
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and an occupational impact. Participants felt a sense of ‘not being normal’ related to 
difficulties and challenges inherent in taking medicines. 
 
Examples from the literature 
 
Side effects of medication: 
 
Participants described side effects from prescribed drugs. One of the participants on 
antidepressants stated, “I was prescribed this medication for mild sleeplessness. I 
became addicted to it and after 18 months of severely debilitating symptoms, the 
principal symptom being persistent suicidal thoughts.”106 
 
Participants expressed severe emotional/mental side effects with antidepressants. For 
example, one participant experienced numbing of both positive and negative emotions, 
and he stated, “There came a point where, alright, I've survived, but what's the point in 
surviving if you can't feel?”107 
 
Feelings about course of drugs: 
 
Participants often felt more ambivalent about medication, particularly when they had 
been on medication for a long time – there was a sense that they were caught in a drug 
loop. As one participant expressed it: “It's a part of my life really and I've just got to cope 
with it.”108 
 
Other participants accepted antidepressants as a long-term intervention and paid little 
attention to the reasons why they continued taking them: “I don't really know. The 
doctors will keep an eye on things and if the time was appropriate then they would take 
me off it but … having kept me on it I assume they are happy for me to go on taking it 
so I take it but ... with all this medication I would come off it if I could. If I can't come off it 
then I accept it.”108 
 
Impact of the drugs on lives 
Some participants felt that treatment with prescribed drugs (specifically antidepressants 
and benzodiazepines) resulted in an overall negative impact on their lives including 
impact on relationships and social life, occupational impact and emotional impact. One 
of the participants noted, “I don’t believe I will ever again be the productive, happy, 
sociable person I used to be because of one 10 minute appointment where a GP 
decided it was appropriate to prescribe me SSRIs with no warning of possible side 
effects.”109 Another participant stated, “I was fully functioning working full time as 
accountant several staff under me, driving socialising dating - fully normal life. All taken 
away from me, driving included.”109 
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Level of confidence in finding 1 
 
The GRADE-CERQual rating of confidence in the findings was moderate in qualitative 
studies, low in studies based on online information, and high in findings from reports 
submitted in the call for evidence. 
 
Finding 2. Patients experience physical, emotional and social effects with withdrawal of 
benzodiazepines, z-drugs, opioids and antidepressants 
Participants described physical and mental side effects that occur when discontinuing 
antidepressants in particular. Participants indicated that withdrawal impacts on 
work/finances and places great strain on essential relationships with close friends, 
children and (or) spouses/partners. 
 




Participants described severe withdrawal symptoms such as sudden changes in 
emotion and mood, crying, insomnia, excessive anxiety and agitation, sweating and 
palpitations, bouts of stomach upsets, nausea, dizziness and headaches. They listed 
many diverse physical and mental/emotional symptoms, often describing how these 
impaired their ability to function normally, thus compounding existing and/or generating 
new feelings of depression and despair. One participant described antidepressant 
withdrawal: “Dizziness, nausea, alternate sweats and chills, unable to stand properly, 
balance affected. Dislike of bright lights, slurred speech, no appetite not even wanting 
liquids, pains in abdomen. Re-started medication, and symptoms increased in severity, 
vomited after 36 hours, once after taking first capsule and soup, saw out of hours doctor 
as blood pressure was raised, heart rate fast and blood in urine – on test strip. 
Continued to worsen. Family members called NHS direct helpline.”106 Another 
participant stated, “withdrawals are so severe I cannot function to do simple tasks like 
make a cup of tea let alone leave the house to go to work.”110 
 
Impact of withdrawal: 
 
Participants described negative impact of withdrawal on their lives, loss of job, loss of 
home, loss of friends. One of the participants noted, “I am unable to work and 
housebound. Withdrawal is the single most gruelling and challenging experience of my 
life and I know that I am far from alone. I understand what is happening to me, many 
don’t and are frightened by it.”109 Participants described working as too “challenging” 
given their symptoms, which often restricted the number of hours they could work, 
and/or the ability to function productively when at work. Participant responses indicated 
that withdrawal placed great strain on essential relationships with close friends, children 
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and (or) spouses/partners. Many indicated the negative impact it exerted on others. 
Participants expressed “… accusations from family of being crazy.”110 One participant 
stated, “It affected my relationships with family members, as my thoughts/feelings 
seemed irrational and my behaviour uncharacteristic and unpredictable.”110 
 
Negative outlook on life due to withdrawal: 
 
Participants still suffering the adverse effects of withdrawal expressed a growing sense 
of hopelessness and pessimism about the future. Many participants widely feared that 
the suffering “would never end” that “there is no way out” and that they would never 
again be able to “function on any level that makes life worth living.”110 One of the 
participants expressed, “I know myself there have been times when I thought of ending 
it all. Lost all hope.”110 Another participant stated, “During withdrawals, I did not realise 
what was happening to me and thought I was dying. It was extremely scary.”110 Some 
participants noted that it sometimes took several attempts to withdraw and some others 
were unsuccessful and had to reinstate the drug as one participant who said, “after 6 
months I reinstated the drug after suffering extensive and recurring withdrawals.”110 
 
Level of confidence in finding 2 
 
The GRADE-CERQual rating of confidence was low in qualitative studies, low in studies 
based on online information, and high in findings from reports submitted in the call for 
evidence. 
 
Finding 3. Patients on benzodiazepines, z-drugs, opioids and antidepressants 
experience barriers to accessing and engaging in treatment and support 
Participants felt there was insufficient, or a lack of, information offered on the side 
effects and withdrawal associated with the antidepressants, benzodiazepines, z-drugs, 
and opioids. They described prescribers not listening to their concerns. Participants 
expressed that there a lack of alternative interventions to drugs (specifically for 
antidepressants and benzodiazepines) and prescription was offered as an apparent first 
course of action. They felt that GPs do not recognise new symptoms as being 
symptoms of withdrawal, and discount patient experience of withdrawal as recurrence of 
the original issue. Participants felt there was a lack of dedicated NHS support. 
 
Examples from the literature 
 
Lack of warning about side effects and dependence: 
  
Participants noted that no warning was given about side effects, and treatment was 
sometimes continued despite drugs not helping and/or severe side effects. One of the 
participants expressed, “GPs and psychiatrists have never warned me of the side 
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effects [of venlafaxine] or difficulties I might face in withdrawal. They have all however 
been very keen to increase dosage and discharge me.”109  
 
Participants expressed that there was a lack of alternative interventions to drugs 
(specifically for antidepressants and benzodiazepines) and prescription was offered as 
an apparent first course of action. One of the participants quoted, “If I had been offered 
a talking therapy 17 years ago instead of mind numbing, habit-forming drugs that my 
life, career and health would be in a much better place than it now is.”109 
 
Lack of access to effective management and support: 
  
Participants described prescribers not listening to their concerns, and that this could 
also be a factor influencing them to seek psychological therapy. One participant stated, 
“we'd all like to think that we're visiting Frasier Crane but we're not, you don't get to lay 
on the couch, you don't get to discuss your problems...you get to go in for 10 minutes if 
you're lucky once every 3 months - 'How are you feeling? Still taking medication? 
Sleeping alright? Well we'll leave you on that then' ... and I've had that for 10 years so I 
guarantee you ... that's what happens."107 Participants perceived an underlying cause 
that was not addressed by medication and one participant reportedly told the GP, "I'm 
on this medication and there's obviously some underlying cause and I'd like to try and 
sort that out.”107  
 
Participants felt that there was lack of access to effective management and informed 
medical oversight of withdrawal process. Participants felt that they were either advised 
to continue with the antidepressant, had their withdrawal misdiagnosed as relapse or 
were recommended inappropriate support (for example, illegal drug use services not 
specific to prescribed drug withdrawal). Participants felt that GPs do not recognise new 
symptoms as withdrawal and discount patient experience of them as unrelated to the 
original issue. As one of the participants noted, “... my psychiatrist wouldn't entertain the 
idea of protracted withdrawal. My psychiatrist kept saying my symptoms were 
[psycho]somatic or medically unexplained.”109 
 
Participants felt there was a lack of dedicated NHS support to access for help. As one 
participant noted, “I regularly saw my GP but they offered no guidance or support.”110  
 
There was disillusionment with medical professionals due to the mismanagement, 
misdiagnosis and denial of withdrawal for example. One participant stated, “They 
dismissed any notion of withdrawal and prescribed a number of different medication.”110  
 
Participants felt that poor monitoring systems in general practice was a cause of long-
term prescribing for benzodiazepines. A submission from an individual affected by 
prescribed benzodiazepine dependence reported they were prescribed 
benzodiazepines regularly after being told by their psychiatrist that, “…like a diabetic 
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needs insulin…”,1 they would always need to take benzodiazepines because of their 
anxiety. 
 
Support provided by mental health crisis teams was similarly experienced as dismissive 
towards “any notion of withdrawal.” One individual referred to their local Youth Crisis 
Team as “frustrating and overwhelming” as withdrawal was not taken seriously. 
Wellbeing Teams were also referred to as “not at all helpful”, and of a social worker, one 
respondent said, “... this person who came over every week ... could only offer 
sympathy and had no idea about this.” NHS 111 was similarly experienced as unhelpful: 
“NHS 111. I asked them if it was OK to take vigorous exercise, spoke to an assessor 
and then a clinician for a total of 30 minutes and the clinician told me to talk to my 
doctor. I rang my surgery and they said if it's not urgent please ring NHS 111.”110 
 
Level of confidence in finding 3 
 
The GRADE-CERQual rating of confidence was moderate in qualitative studies, low in 
studies based on online information, and high in findings from reports submitted in the 
call for evidence. 
 
Current practice examples 
The question addressed in the rapid evidence assessment in relation to current practice 
examples was: 
 
“What are the current existing examples of services providing withdrawal support and 
what is the effectiveness and cost-effectiveness of the health/social service delivery 
models that prevent or treat dependence and the short term discontinuation or longer 
term withdrawal symptoms from the following prescribed medicines: opioids for chronic 
pain (excluding end of life/palliative care/cancer pain), benzodiazepines, z-drugs, 
gabapentin and pregabalin (excluding epilepsy treatment), and antidepressants? (In 
England, as well as health service delivery models in other countries that might inform 
provision in England).” 
 
The time frame used was 2008 to 2018, and papers did not have to appear in peer 
reviewed journals but would have to be publicly available, for example on an 
organisational website or in a publicly available annual report. 
 
As a result of the call for papers and literature search a total of 4 articles describing a 
total of 7 services, were included within the review.111-114 Three of the included services 
were specific to opioid use. The remaining 4 covered a mixture of prescription drugs 
including benzodiazepines, z-drugs and antidepressants. In addition to the included 
studies, further submissions provided descriptions of programmes of interest which 
were in the public domain, but no evaluation or outcome measurements were available 
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at present that could be analysed within the report to show effectiveness of the service. 
These are excluded from the analysis but are listed and briefly described in appendix F. 
 
To ensure quality assessment was incorporated into this review, an assessment of risk 
of bias at the study level was performed using the Institute of Health Economics (IHE) 
Quality Appraisal of Case Series Studies checklist.  
 
Main findings 
The limitations in the evidence mean it is not possible to make any firm conclusions on 
the effectiveness of current practice examples within the UK, and the studies included 
gave only limited insight into the effectiveness of existing UK services for prescribed 
medication dependence in terms of patient outcomes and the cost of these services. 
Although all of the studies that reported on reduction in dose/cessation of prescribed 
drugs indicated that a certain proportion of service users did benefit from the services in 
terms of reducing dose/ceasing use completely,112-114 the proportion benefitting varied 
across individual services, the period over which data was collected was short, or data 
were collected from a small number of participants relative to the population served. 
There was also a very limited description of the service and components of the service 
in some cases. These factors mean that it was difficult to determine the effectiveness of 
the services over a longer time. For example, details of the proportion who may relapse 
later are not available, and limited descriptions of some of the services make it difficult 
to identify key components of services that may work well. These issues, among others 
specific to each individual study, resulted in all included studies being considered at 
high risk of bias, and the non-comparative nature of all the studies meant that 
differences between those using a service and those not using a service or using an 
alternative service could not be compared. 
 
Despite the limitations of the evidence, some key themes within existing UK services 
were identified. These are described below and summarised at the end. 
 
Summary of the literature 
Opioid reduction/withdrawal services within the UK 
 
Two conference posters were included in the review.112, 114 One112 described an existing 
opiate reduction service that had been developed within a primary care practice and the 
other114 described a pilot intervention performed across 2 GP practices that aimed to 
help patients understand their relationship with opioids and develop non-drug-based 
methods of managing pain. Information concerning the components of the services was 
very limited and reporting of the outcomes was brief however both reported that a 
proportion of service users were able to completely cease opioids or reduce their dose. 
One112 reported that 28% of participants were able to cease use of opioids and 70% 
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significantly reduced their dose over 2 months, while the other114 indicated that 44% (15 
out of 34) service users reduced their dose of opioids over an unreported period of time, 
including 3 (9%) who ceased use completely. The same study114 reported 
improvements in Current Opioid Misuse Measure (COMM) scale score, Brief Pain 
Inventory (BPI) severity and interference, Warwick-Edinburgh mental wellbeing scale 
and TOP quality of life scores (overall, physical and psychological), but a worsened 
percentage pain relief score, at follow-up compared with baseline although the length of 
follow-up was unclear. 
 
One of the studies112 reported that becoming ‘opiate aware’ as a primary care practice 
had led to a reduction in the initiation of long-term opioid prescriptions, and the patients 
off opiates identified a higher quality of life (significant), lower anxiety (non-significant) 
and higher activity level (non-significant) in comparison with those on high-dose opiates. 
 
Both studies were rated as being at a high risk of bias. The primary limitations were that 
very limited information was provided about the services, the period outcomes were 
measured over was short or was not reported and they are non-comparative reports. 
 
Mixed drug reduction/withdrawal services within the UK 
 
A document produced by the All Party Parliamentary Group for Prescribed Drug 
Dependence (APPG PDD)113 describes 4 existing UK services for prescription 
medication withdrawal: 
 
Prescription Medication Support Service: 
 
A service in Wales that covers benzodiazepines and z-drugs, antidepressants, pain 
killers (within prescribed limits) and other drugs (not specified). The key features of this 
service are that it involves medication therapists (nurses/counsellors) that are based 
within GP surgeries and collaborate with pharmacists and GPs to contact target client 
groups directly. Education and training are provided through workshops and talks, and 
personalised programmes for patients are developed following assessment. Support is 
available for patients in the form of monthly in-person follow-up, and telephone support 
available in between appointments. The key information reported for this service was:  
 
• reduction/cessation in prescribed drug use – of 329 people using the service 
between April and September of 2018, 62% were reducing prescribed medications 
and 33% had ceased taking them 
• cost outcomes – the service covers a population of 701,000 across 6 counties, at a 
cost per annum of £179,000, a cost per population head of £0.26 per year and a 
cost per person helped of £272 per year 
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The main limitations of the information reported for this service were that 
reduction/cessation outcomes were only available over a 6-month period and that the 
service covers over the counter pain killers, which were specified as an exclusion 
criterion for this project as well as other, unspecified drugs. 
 
Bristol and District Tranquilliser Project (BTP): 
 
A service in England that covers benzodiazepines and z-drugs, and antidepressants. 
Antipsychotics are addressed on GP request only. The service does not work with pain 
killers. The key features of this service are a helpline that supports the Bristol 
community and rest of the UK, with additional services available for Bristol residents 
only, where necessary, including weekly support groups and counselling. Non-Bristol 
residents can continue to use the helpline for support. The services are delivered by 
people with personal experience of prescribed drug dependence and prescriber 
permission is required before clients are given the opportunity to establish 
stabilising/tapering plans via the service. The key information reported for this service 
was:  
 
• reduction/cessation in prescribed drug use – of 285 people helped in 2017/18, 83% 
commenced withdrawal, but there is no mention of the proportion that successfully 
completed withdrawal 
• cost outcomes – the service covers a Bristol population of 450,000, with an annual 
expenditure of £91,200, a cost per head of £0.20 per year and a cost per person 
helped of £320 per year 
 
The main limitations of the information reported for this service were that 
reduction/cessation outcomes were only available over one year, it was unclear whether 
the costs reported factor in those helped UK-wide via the helpline, and it covers 
antipsychotics (albeit only 1% of client group) which are excluded from this review. 
 
The Bridge – Addiction to Medicines Programme: 
 
A service delivered by a charity in Bradford, England, which is a sub-contractor to a 
larger substance misuse service. The service covers benzodiazepines and z-drugs, and 
opioid pain killers. It does not work with antidepressants. The service works with GPs to 
identify patients for proactive contact. 93% of referrals are from GPs. Meetings are 
arranged with Bridge contact workers, where assessments are performed and a support 
plan is designed. Support is provided for tapering, and prescription adjustments are 
provided by GPs, and follow-up meetings with Bridge workers with tailored individual 
support are arranged. Telephone support is also available. The key information reported 
for this service was:  
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• reduction/cessation in prescribed drug use – of 364 people who were helped in 
2016/17, there were 43.3% successful completions for benzodiazepines and 47.4% 
successful completions for opioids (however, it is unclear what ‘successful 
completion’ refers to and whether this indicates successful reduction or cessation) 
• cost outcomes – the service covers a population of 532,000, with an annual 
expenditure of £98,000, a cost per population head of £0.18 per year and a cost per 
person helped of £269 per year. 
 
The main limitations of the information reported for this service were that 
reduction/cessation outcomes were only available over one year and it is unclear how 
‘successful completion’ was defined. 
 
Recovery Experience Sleeping Tablets and Tranquilisers (REST): 
 
A service run by a charity called Mind, in Camden, England. The service covers 
benzodiazepines and z-drugs only. The key features of this service are that it is run by 
non-clinicians in a community setting, with an intention and ability to work with the NHS. 
The manager of the service and service users undertake networking and provide 
education in the area (no further details about this were provided in the report). The 
main aim of the service is to stabilise patients’ use of prescribed drugs before reducing 
or withdrawing. The support available includes advice via a helpline, one-to-one 
tapering advice, and counselling with tapering support (no description of what type of 
tapering support is provided in the report). It was noted that there is a 2-3 month wait for 
the counselling component of the service. In addition, weekly peer support groups and 
monthly family support groups are available, and other help can be provided such as 
accompanying service users to GP appointments or assisting with benefits and housing. 
The key information reported for this service was:  
 
• reduction/cessation in prescribed drug use – of 194 people who received counselling 
support over the last 8 years (as of March 2018), 4% stabilised their dose, 51% 
lowered their dose, 29% withdrew completely, 6% had no change in dose, 1% were 
on a higher dose and the outcome of the service was unclear/not applicable for 21% 
of service users; the length of follow-up for each individual is also unclear from the 
report 
• cost outcomes – the service covers a population of 215,667, with 130 people helped 
annually through the helpline and counselling services combined; the service cost 
per annum was reported to be £49,000, with a cost per head of population of £0.22 
per year and a cost per person helped of £376 per year 
 
The main limitations of the information reported for this service were that outcomes 
were only given for those who used the counselling service (outcomes for the helpline 
not included) and a relatively low number of people used the counselling support, 194 
over an 8-year period. 
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Improving the use of prescription drug monitoring programmes: 
 
One study111 reported information on a pilot intervention in the USA that assessed the 
use of an academic detailing interventionxiv to improve the use of a prescription drug 
monitoring programme by primary care physicians. This involved interactive sessions 
between academic detailers and primary care physicians on using and registering with 
the monitoring database. The study only reported preliminary findings regarding the 
feasibility and acceptability of the intervention by primary care physicians. 
 
The key information reported for this pilot intervention was:  
 
• delivery of the academic detailing sessions incurred problems, with 8% of primary 
care physicians not able to complete the real-time experience using the prescription 
drug monitoring database during the allocated time, which was a key component of 
the session – reasons for this included time constraints and issues logging into the 
database 
• physicians also reported on potential barriers to using the database in practice – 43 
of 75 reported at least one potential barrier, including time constraints, the database 
not being user friendly and it requiring practice to remember how to run the reports 
 
The main limitations of this pilot intervention were that it was performed in the USA, it is 
unclear how relevant this type of intervention is to the UK setting and there are no 
outcomes concerning the effect on prescribing or patient use of prescription drugs. This 
study was considered to be at high risk of bias. Despite this, the outcomes that could be 
considered to reflect ‘staff satisfaction’ with this type of intervention designed to change 
prescribing practice. If a similar service/intervention was considered in the UK, it gives 
some insight into the potential barriers or issues that could arise in designing and 
delivering it. 
 
Key components of the services 
  
All the UK services/interventions described involvement of GP/primary care services. 
This involvement ranged from services being developed and based within primary care, 
to community-based services run by non-clinicians who had the ability to communicate 
and work with the NHS. In addition, many of the services identified offer helpline and 
telephone support as well as further services such as counselling/support groups, and 
individualised plans and programmes were a focus. Most services identified were small 
                                            
 
 
xiv Academic detailing is interactive educational outreach to physicians to provide unbiased, non-commercial, evidence-based 
information about medications and other therapeutic decisions, with the goal of improving patient care. It is usually provided to 
clinicians one-on-one in their own offices. The approach is based on the effective communication/behaviour change/marketing 
approach. (Introductory guide to academic detailing, NARCAD) 
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in terms of the number of staff involved and covered areas of variable sizes (population 
and area). 
 
In conclusion, the evidence identified for this review is too limited to make firm 
conclusions in terms of UK best practice, though key features that were common to  
the existing UK services included in this review were a degree of GP or other primary 
care involvement and the combination of a helpline service with further support in the 
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5. Conclusions and recommendations 
Attention already being paid to these issues 
A lot of work that might have been recommended by the review has already started or 
will do so shortly, prompted by some of the same concerns that drove the review or 
sometimes by knowledge of the review itself. There are many examples of this and just 
a few are: 
 
• England’s Chief Pharmaceutical Officer, Dr Keith Ridge, was asked by the Secretary 
of State to review overprescribing in the NHS, addressing ‘problematic 
polypharmacy’ (where a patient is taking multiple medicines unnecessarily) and how 
to help patients come off repeat prescriptions they no longer need 
• the National Institute for Health and Care Excellence (NICE) was asked by the 
Department of Health and Social Care to develop a quality standard covering safe 
prescribing of drugs associated with dependence and the careful management of 
withdrawing from these drugs – it is also already developing or updating guidance on 
chronic pain management, the treatment of depression and other topics relevant to 
medicines liable to dependence and withdrawal 
• an expert group of the UK’s Commission on Human Medicines (CHM) has been 
reviewing the benefits and risks of opioid medicines, including dependence and 
addiction, and has made new warning label recommendations to the Medicines and 
Healthcare products Regulatory Agency (MHRA) that have been accepted. 
Packaging on opioid medications will have to carry a warning that informs patients 
about the risk of addiction 
• the Royal College of Psychiatrists published a position statement on antidepressants 
and depression, setting out “the College’s view on promoting optimal use and 
management of antidepressants. It discusses the challenges with prescribing 
antidepressants, including considering the evidence around efficacy, benefits and 
harms, ensuring they are used when clinically indicated and managing withdrawal. 
The statement includes [a] range of recommendations aimed at the UK Health 
Departments, national bodies and commissioners” 
• Keele University has been awarded an NIHR programme grant to investigate ways 
to reduce inappropriate opioid prescribing in primary care by working with clinical 
pharmacists who will be trained to offer alternative pain management strategies 
• the University of Warwick has a randomised controlled trial of a self-management 
intervention to improve the wellbeing of people with opioid-treated chronic pain and 
a Health Foundation-funded project testing an electronic intervention with 
prescribers to improve medication selection and dispensing, to reduce costs and 
polypharmacy – the latter project is not targeted at specific medicines but opioids are 
expected to be a cost-priority for some organisations 
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• the University of Sheffield has been studying the extent and nature of opioid 
analgesic dependence in primary care 
• the Centre for Epidemiology Versus Arthritis at Manchester University is assessing 
patterns of opioid use and comparative opioid safety for non-cancer pain, seeking to 
identify subgroups of patients at an increased risk of chronic opioid use 
• Public Health England (PHE), with NHS England and Versus Arthritis, has published 
a 5-year framework for preventing musculoskeletal conditions –opioids, 
gabapentinoids and benzodiazepines are all used to treat these conditions 
• PrescQIPP audit tools are available to support primary care practices and 
community pharmacists to review and tackle high dose opioid prescribing 
 
The review’s conclusions 
The analysis of NHSBSA data for this review showed that, in England in 2017 to 2018, 
around one in 4 adults had a prescription dispensed in the community for one of the 
medicines in scope. For antidepressants alone, this figure was around one in 6 adults. 
 
The number of patients prescribed medicines liable to dependence or withdrawal, and 
the prescriptions for them, have varied by class over the last 3 years and prior to that: 
 
• antidepressants and gabapentinoids have seen a rise that continues the trends seen 
in previous years, but with antidepressants at much larger numbers (71 million 
prescriptions in 2018, and 7.3 million people in 2017 to 2018) and gabapentinoids a 
greater rate of increase 
• opioid pain medicines have continued to fall, a trend started recently after years of 
increases 
• a fall in benzodiazepines has continued 
• a longer-term increase in z-drugs started to reverse in 2014 
 
The longer-term trends referred to above show: 
 
• dispensed prescriptions for benzodiazepines falling since 2008 and earlier to under 
8 million in 2018 
• z-drugs peaking in 2014 at more than 6 million prescriptions a year and then starting 
to fall, after an earlier rise as they replaced benzodiazepines for insomnia 
• opioid pain medicine prescriptions rising from the mid-1990s to 24 million in 2016, 
before starting to fall  
• gabapentinoids increasing sharply (from under a million prescriptions in 2008 to 7 
million in 2018) 
• antidepressants rising in a straight line from 2008 and earlier (prescription numbers 
doubling in the 10 years 2008 to 2018 from 36 million to 71 million) 
 
Age and sex impact on the rates of prescribing, with women and older adults being 
prescribed to at higher rates (though this would be expected for older adults who will 
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develop more long-term conditions needing treatment). There is also substantial 
variation in the rates of prescribing at CCG level, even after adjusting for age and sex. 
The overall rate of prescribing, prescribing duration and the rate of prescribing more 
than one class of medication to an individual all increase with higher rates of 
deprivation. 
 
It is difficult to determine the prevalence of dependence on, or withdrawal from, the 
medicines covered in the review from any available data sets, but the data on the 
duration of prescribing suggests that dependence and withdrawal are likely to be 
significant issues, particularly when seen together with the significant concerns raised 
by some patients, campaigners and others. 
 
The data on the duration of receipt of a prescription is particularly significant in relation 
to opioid pain medicines and benzodiazepines. Long-term prescribing of opioids for 
chronic, non-cancer pain is not effective for most patients and guidelines specify that 
benzodiazepines should not usually be used for longer than 2 to 4 weeks. 
 
It is important to recognise that long-term prescribing – in some circumstances and for 
some patients – may be clinically appropriate. For example, antidepressants are 
recommended for longer-term treatment for some people, including to prevent relapse 
to depression. 
 
Personalised care, shared decision making with patients, informed choice, and regular 
and purposeful review are all central tenets of effective clinical practice. Such practice is 
an important safeguard against people being left for too long on any medicine, and 
developing dependence or experiencing withdrawal, which may outweigh any benefits 
they derive. 
 
The data analysis shows there is a significant population who were already in receipt of 
a prescribed medicine at the point when the data starts in April 2015. A significant 
proportion of them were still in receipt of the same class of medicine 3 years later. Of 
those who started new prescriptions in the period, much smaller proportions are going 
on to receive prescribing long term, but those who do add to a growing cohort in long-
term prescribing. At least half of those with a prescription at March 2018 had been in 
receipt of a prescription for at least 12 months, a proportion that has gradually increased 
since 2016 and should be expected to continue to increase if this trend persists. 
 
In the CCG level data, if longer-term prescribing of one class of drug is evident, it is also 
likely to be seen in other classes. This is particularly apparent with antidepressants, 
opioid pain medicines and gabapentinoids, where higher rates and higher proportions 
with longer prescribing durations in one of these classes in a CCG tend to mean the 
same in the other classes. 
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Any focus on longer-term prescribing must not be allowed to generate unintended 
negative consequences. Stigmatising the appropriate and safe use of potentially helpful 
medicines may stop people from benefiting from them. And inappropriately curtailing or 
limiting the use of medicines may increase harm, including the risk of suicide. There is 
also a very real and significant risk that poorly managed or blanket ‘deprescribing’, with 
people receiving inadequate support, could lead to people seeking medicines from illicit 
or less-regulated sources, including online, or even resorting to illicit drugs to treat their 
symptoms or prevent withdrawal. 
 
Patients may come to medical appointments with a clear expectation that medicines will 
meet their needs, and some will assertively make a case to receive a prescription. 
Increased awareness among the public and clinicians of treatments that are alternative, 
or supplementary, to medicines, and of the risks and benefits of medicines, is vital.  
 
Recurring patterns are evident in the history of medicines that may cause dependence 
or withdrawal. New medicines are seen as an important part of the solution to a 
condition, resulting in widespread use. Their dependence or withdrawal potential are 
either unknown at this point, due to a lack of research, or perhaps downplayed. As 
evidence of harm from dependence or withdrawal emerges, efforts are made to curtail 
prescribing. The repetition of this pattern is striking and clearly illustrated in the context 
section of this review.  
 
A key conclusion from the rapid evidence assessment (REA) was that, in the last 
decade, there is only a small amount of high-quality research from which firm 
conclusions related to dependence can be drawn – more high-quality research is 
therefore needed on issues related to dependence and withdrawal. Any high-quality 
relevant evidence was usually taken from trials, often industry-funded or commissioned, 
where the primary aim of the study was to establish the efficacy of the medicine. Such 
trials are also often not designed to detect harms that may occur relatively infrequently. 
Limited high-quality evidence on risk factors and harms of dependence or withdrawal 
was identified. 
 
The call for evidence provided detailed descriptions of patients’ experiences around the 
harms caused by dependence or withdrawal and the support, or lack of it, they received. 
Some patients experience physical, emotional and social effects with withdrawal of 
benzodiazepines, z-drugs, opioids and antidepressants. Patients listed many diverse 
physical and mental or emotional symptoms, often describing how these impaired their 
ability to function normally, thus compounding existing, or generating new, feelings of 
depression and despair that affected relationships, mental health and work. In some 
cases, withdrawal symptoms were reported in the longer term, for many months or 
years. 
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Patients on benzodiazepines, z-drugs, opioids and antidepressants experience barriers 
to accessing and engaging in treatment and support for dependence or withdrawal. 
Patients described a lack of information on side effects and withdrawal as well as 
feeling doctors and other prescribers did not acknowledge withdrawal or did not 
recognise it as such, sometime diagnosing a return of the original condition. They 
described not being offered any non-medicinal treatment options, a lack of review, and 
a lack of access to effective management and NHS support services. 
 
Evidence on patients’ experiences of gabapentinoids was lacking and therefore more 
research is needed. However, the recommendations of this review will also be relevant 
to this class of medicines, based on the evidence outlined in the context section of the 
review. In the context of the significant limitations of the evidence identified in the REA, 
no firm conclusions can be drawn regarding the most effective approach to the 
prevention and treatment of dependence and withdrawal symptoms from prescribed 
medicines from the published evidence base, although there is some weak evidence of 
benefit for patient education or support programmes. 
 
The call for evidence provided a description of small-scale services in the UK that are 
available but no robust comparable evidence on the effectiveness and cost 
effectiveness of different approaches is available, leading again to the conclusion that 
more research is needed. However, some common features were identified, including 
the involvement of primary care services in support services, the offer of helpline 
telephone support, tapering support, counselling and support groups, and individualised 
plans and programmes. As these services seem to be well used and received, it is 
reasonable to conclude that these components should be considered in the 
development of support for these patients.  
 
From the patients’ experiences papers submitted in the call for evidence it can be 
concluded that it is very important to patients that they are consistently informed about 
non-medicinal treatments and the benefits, harms and risks of taking medicines that 
may cause dependence or withdrawal. Furthermore, patients said that withdrawal was 
not always recognised by clinicians, which indicates a need for further research and 
training. 
 
Finally, it is important that treatment pathways are available to patients who experience 
problems with dependence or withdrawal, which meet their support needs in relation to 
withdrawal and related conditions, and reduce the risk of relapse and harm. Clinicians 
need the time and resources to explore these options with patients. These pathways 
might include referrals to mental health teams, IAPT (Improving Access to 
Psychological Therapies) services, support groups, pain clinics, social prescribing 
navigators and, in some local arrangements, where more complex cases are identified 
that cannot be treated in primary care or specialist services where they exist, to 
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addiction services. Many of the actions outlined in the NHS Long Term Plan, published 
in January 2019, will address some of these issues. 
 
The review’s recommendations 
The recommendations of this report are just the beginning of the way forward – all parts 
of the healthcare system and the general population will need to engage with this 
complex issue, developing solutions and responses over time. The strategic leadership 
of CCGs, integrated care systems (ICS) and sustainability and transformation 
partnerships (STPs) at local level will be vital. The recommendations therefore focus on 
ensuring that different elements of the healthcare system pay greater attention to the 
issue, building awareness and enhancing decision making, and supporting people 
currently experiencing problems. 
 
Recommendations from the review fall into 5 broad areas: 
 
1. Increasing the availability and use of data on the prescribing of medicines that 
can cause dependence or withdrawal to support greater transparency and 
accountability and help ensure practice is consistent and in line with guidance. 
2. Enhancing clinical guidance and the likelihood it will be followed. 
3. Improving information for patients and carers on prescribed medicines and other 
treatments, and increasing informed choice and shared decision making between 
clinicians and patients. 
4. Improving the support available from the healthcare system for patients 
experiencing dependence on, or withdrawal from, prescribed medicines. 
5. Further research on the prevention and treatment of dependence on, and 
withdrawal from, prescribed medicines. 
 
1. Increasing the availability and use of data 
It is recommended that: 
 
1.1. In addition to the CCG indicators published in the spreadsheet accompanying 
this report, PHE or the NHS Business Services Authority (NHSBSA) publish this 
review’s data on the prevalence and duration of the prescribing of medicines 
that can cause dependence or withdrawal, at clinical commissioning group 
(CCG) and practice levels. 
1.2. PHE and the NHSBSA work together to establish the feasibility of publishing 
regularly updated data on the prevalence and duration of the prescribing of 
medicines that can cause dependence or withdrawal at CCG and practice 
levels, establishing which measures would most effectively supplement the data 
the NHSBSA currently publishes. As part of this process, consideration should 
be given to allowing third parties with relevant expertise to analyse and present 
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existing and new prescribing data to enhance transparency and support 
improvements in practice. 
1.3. Commissioners, primary care staff and clinicians, including clinical pharmacists, 
use available data on prescribing patterns to identify need in relation to 
dependence on or with withdrawal from prescribed medicines, with training 
made available to allow them to do this effectively. 
1.4. The Care Quality Commission (CQC) uses data on the prescribing of medicines 
that can cause dependence or withdrawal to inform their inspections of primary 
care. 
1.5. Regional Medicines Optimisation Committees look at variations in prescribing 
practice to inform the medicines optimisation support they provide to local areas 
and work with ICS and STPs to support changes in practice, where appropriate. 
1.6. NHS England & NHS Improvement (NHSE&I), NHSBSA and the Department of 
Health and Social Care (DHSC), with input from PHE, review the data collected 
nationally on prescribing to establish whether it can be enhanced to provide 
better intelligence on prescribing practice to support improving, and monitoring 
variations in, that practice. 
NHSBSA dispensing data is primarily collected to support the reimbursement of pharmacists and as 
such its utility for other purposes is limited. However, the data has been used for a number of other 
purposes, including to support transparent audit, and to review and benchmark GP prescribing 
practice. It has also informed guidelines and supported academic studies. 
 
1.7. NHSE&I ensure that the work of their Medicines Safety Programme is aligned 
with, and responds to, the findings of this review. 
 
2. Enhancing clinical guidance and the likelihood it will be followed 
It is recommended that: 
 
2.1. NICE enhances its focus, in the context of the findings of this review, on 
medicines that can cause dependence or withdrawal when developing or 
reviewing relevant prescribing recommendations, including withdrawal 
management and reviewing prescriptions. It may be appropriate that, when 
reviewing or developing recommendations, NICE places a greater emphasis on 
withdrawal management and support, to better balance the important emphasis 
to date on ensuring people have access to medicines they may benefit from. 
NICE should also undertake a targeted review of all output including 
commissioned products, guidelines and technology appraisals that recommend 
the prescribing of opioid pain medicines.  
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2.2. Following the development of its planned guideline and quality standard on ‘safe 
prescribing and withdrawal management of prescribed drugs associated with 
dependence and withdrawal’, NICE and NHSE&I work together to support its 
implementation and consider the implications of this guidance on the relevant 
condition-specific guidance it publishes. 
2.3. NICE considers including information to help shared decision making, including 
the development of decision aids, during development of its guidance on safe 
prescribing and withdrawal management of prescribed drugs associated with 
dependence and withdrawal. 
2.4. Regional Medicines Optimisation Committees continue to develop prescribing 
and medicines safety protocols for local implementation, and include a focus on 
the safe prescribing of medicines that can cause dependence or withdrawal, 
including review and withdrawal management or, where appropriate, ending 
prescribing. 
2.5. NHSE&I look at the potential for the new service specification on structured 
medication review, which forms part of the new primary care network 
arrangements through the GP contract, to address medicines that can cause 
dependence or withdrawal. 
2.6. As new clinical pharmacists are deployed across primary care, NHSE&I 
continue to ensure that their role in medication reviews has sufficient focus on 
medicines that can cause dependence or withdrawal. 
2.7. NHSE&I evaluate the impact of the medicines safety quality improvement 
module of the Quality Outcomes Framework (QOF) and explore the feasibility of 
enhancing safer prescribing practice for medicines that may that cause 
dependence. 
2.8. The relevant medical colleges and other professional bodies continue to provide 
leadership, and publish briefings and resources, including information on 
withdrawal and dependence, to support effective and safe prescribing. 
The Faculty of Pain Medicine, Royal College of Anaesthetists, Royal College of General Practitioners, 
Royal College of Surgeons and partners are “establishing an evidence-based clinical framework to 
facilitate local decision-making and policy regarding opioid management perioperatively [at or around 




2.9. The General Medical Council, Academy of Medical Royal Colleges and Medical 
Schools Council provide advice or support to help ensure that curricula for 
medical education and training to adequately address issues related to 
dependence on and withdrawal from prescribed medicines, at undergraduate, 
foundation and postgraduate levels. 
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2.10. Health Education England reviews the training and educational resources 
available to health practitioners on prescribing medicines that can cause 
dependence or withdrawal, and on supporting people who are experiencing 
problems. 
2.11. Pharmaceutical industry influence on, and involvement in, training and activities 
is transparent and monitored to help ensure objectivity and independence. 
2.12. NHS trusts, third sector drug treatment service providers, local authority drug 
treatment commissioners and Health Education England local offices work 
together to provide training places for addiction psychiatrists, who have a role in 
supporting local areas with their expertise and, dependent on local 
arrangements, can work with people with the most complex needs in relation to 
dependence on, and withdrawal from, prescribed medicines. 
2.13. As part of its opioids review the Commission on Human Medicines (CHM) 
examines the evidence and related guidance on over-the-counter opioid 
medicines (principally those containing low-dose codeine, usually in combination 
with another, non-opioid, painkiller), and considers options for reducing easy 
access to them. 
2.14. The Medicines and Healthcare products Regulatory Agency (MHRA) and CHM 
consider how risks of dependence on, and withdrawal effects from, medicines 
might be further assessed as part of requirements for marketing authorisation 
applications and in post-authorisation pharmacovigilance. 
 
3. Improving information for patients and increasing informed choice 
It is recommended that: 
 
3.1. As part of their commitment to universal personalised care, NHSE&I ensure 
there is a significant focus on medicines that may cause dependence and 
withdrawal in medicines reviews and in work to improve shared decision making 
between patients and clinicians. 
 
NHSE&I are already working to raise public awareness about the need to be involved in shared 
decision making and to train the workforce to deliver it. This programme of work will begin by training 
clinical pharmacists in primary care networks to host medication reviews with an emphasis on 
medicines safety and on medicines that cause dependence or withdrawal. Shared decision-making 
supports patients to understand the options available to them, alongside what is known of the 
benefits, harms and consequences of those options. Options may include psychological treatment 
including IAPT, self-management education, health coaching or less structured interventions such as 
peer support or other social prescribing options. Over the next 5 years, NHSE will train over 75,000 
professionals in shared decision making and is working with HEE and RCGP to deliver this. 
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3.2. Building on its review of opioids, the Commission on Human Medicines 
considers evidence and guidance on the labelling of other medicines that may 
cause dependence or withdrawal to ensure patients are clearly alerted to the 
dependence and withdrawal potential. 
3.3. NHSE&I, MHRA, CCGs and primary care services ensure that accurate and 
accessible information is available to patients on the benefits and potential 
harms of medicines that may cause dependence and withdrawal, and, as part of 
its inspections of primary care, CQC assesses the availability and quality of this 
information. 
3.4. As part of its regulatory processes, CQC takes into account the availability of 
accessible information for patients, appropriate to their needs and the care 
delivered. Where relevant this would include information about the potential 
harms of medicines that may cause dependence and withdrawal. 
3.5. The Government, through its relevant organisations, including NHSE&I, 
investigates and researches marketing routes that deliver personalised 
interventions, messages and tools to engender and support behaviour change, 
including in the expectations and use of prescribed medicines that may cause 
dependence or withdrawal, to support the public to make informed decisions 
about risks, benefits and treatment options.  
3.6. Local health and social care commissioners ensure that treatment pathways are 
available to patients who experience problems with dependence or withdrawal, 
which meet their support needs in relation to the underlying or related 
conditions. Clinicians must have the time and resources to explore these options 
with patients. These pathways should include pain clinics, mental health teams, 
IAPT services, support groups, and social prescribing link workers. 
3.7. PHE continues to support the development of evidence and approaches that 
underpin a broad focus on psychosocial responses to mental distress, problems 
and illness, including understanding the relationship between social 
determinants, psychosocial factors and health outcomes, while recognising that 
pharmacological treatment can play an important role: 
www.gov.uk/government/publications/psychosocial-pathways-and-health-
outcomes  
3.8. PHE and the healthcare system continue and enhance efforts to promote 
effective self-care in relation to good mental health, through campaigns and 
support such as PHE’s Every Mind Matters campaign. 
Every Mind Matters is a new national mental health campaign, due to launch in October 2019 
following a pilot programme, which seeks to improve understanding of mental health among the 
general population, help people recognise that their mental health is as important as their physical 
health, and build people’s knowledge and confidence to take positive steps to look after their mental 
health and support others. 
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4. Improving the support available from the healthcare system 
It is recommended that: 
 
4.1. The NHS locally works with local authorities to commission the tiered support 
previously recommended by PHE.115 Depending on local needs and 
circumstances, the response should be developed by local primary care 
services, involving pain and addiction specialists, and peer support groups. 
4.2. Primary care services, clinical and community pharmacists, and GPs develop 
their knowledge of, and competence to identify, assess and respond to, 
dependence or withdrawal associated with some medicines and the support 
needs of people experiencing problems with withdrawal or dependence. 
4.3. DHSC considers supporting the development of a time-limited national helpline 
and associated website to provide expert advice and support to patients while 
changes in practice, prevention activities and support services scale up to meet 
support needs. Any helpline and website services should be developed in 
consultation with key stakeholders (including experts by experience) and in line 
with guidance and relevant standards, and with appropriate clinical oversight. A 
helpline service would provide patients with a combination of support and 
guidance, to include: 
• drug information, including common side effects, information on dosages 
and typical duration of treatment 
• advice on withdrawal, including tapering, with medical support and what to 
expect  
• information on withdrawal symptoms especially regarding symptoms and 
suggestions for coping strategies 
• patient rights and advocacy information 
• details of local specialist in-person support services 
• discussion of options for non-drug alternatives to help patients cope with the 
underlying issues, as well as coping with withdrawal symptoms 
• information and advice for carers and family members 
 
4.4. The associated website is developed to act as a prescribed medicine 
dependence and withdrawal resource, including evidence-based information – 
for patients, doctors and other prescribers, and other healthcare professionals – 
on the medicines, effects and side effects, and advice on shared decision 
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5. Further research 
5.1. Isolating withdrawal effects (especially of antidepressants) from the original 
disorder and its return. 
5.2. Better understanding the incidence, duration, nature and severity of withdrawal 
from antidepressants, including long-term and enduring side effects. 
5.3. Optimal recommended withdrawal regimes for each of the classes of medicines 
covered in the review, while recognising the importance of individualised care. 
5.4. Determinants that result in higher risk of dependence or of experiencing 
withdrawal: systemic factors, prescriber behaviour and individual (patient) 
factors. 
5.5. Harms of dependence or withdrawal from prescription medicines, including 
impact of dose and duration of treatment, particularly for people who are already 
dependent. 
5.6. Prevention or treatment of dependence or withdrawal caused by prescription 
medicines 
5.7. Patients’ experiences (from qualitative studies) of harms of dependence or 
withdrawal associated with prescription gabapentinoid use. 
5.8. Published service evaluations of existing services including service level 
outcomes, patient outcomes and cost effectiveness. Following on from this, 
practice standards and model service specifications could potentially be 
developed to support local areas. 
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Appendices  
Appendix A. Medicines included in the scope of the review and in the data 
analyses 
This list refers to codes from BNF version 68. 
 
Medicine class 
(for this analysis) 
BNF chapter Drugs included 










Morphine (including with cyclizine) 





Tramadol (including with paracetamol) 
4.7.1 Codeine with paracetamol = co-codamol* 
Dihydrocodeine with paracetamol = co-
dydramol* 
 Z-drugs 4.1.1 Zaleplon 
Zopiclone 
Zolpidem  














4.3.1 (Tricyclics) Amitriptyline (including with perphenazine) 
Amoxapine 
Clomipramine 
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Medicine class 
(for this analysis) 















































* Although they are captured within different BNF chapters, codeine and co-codamol, 
and dihydrocodeine and co-dydramol, were regarded as single drugs when considering 
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Appendix B. Issues not included but meriting further consideration 
Secure environments (drafted by Dr Caroline Watson) 
The number of people prescribed medicines in secure environments that may cause 
dependence or withdrawal has increased, reflecting the trend in community prescribing 
of DFMs. These medicines are most commonly prescribed for persistent pain but may 
also be prescribed for anxiety or epilepsy. A recent audit of gabapentinoid prescribing in 
secure environments in the East of England (April 2019) has shown that prescribing has 
doubled since a similar audit in 2012. 
 
First-night reception screening includes questions to detect dependence on over-the-
counter and prescribed medication as well as use of illicit substances. However, in 
reality, dependence on prescribed medicines is rarely acknowledged on entry into the 
secure environment and urine drug tests detect only illicit drugs and opioids. While there 
is a clear pathway for referral to substance misuse teams for support of people using 
and misusing illicit substances, it can be challenging to provide a holistic 
multidisciplinary approach to reduction or cessation of inappropriate prescribed 
medication. 
 
The medicines reconciliation process, which should be carried out within 72 hours of 
arrival, is an important initial step in optimising prescribing on entry into a secure 
environment and it can be viewed as an opportunity to review all prescribed medicines 
for ongoing clinical need. If, on review of medicines prescribed in the community, there 
is no clear ongoing clinical indication for a dependence forming medicine, or there are 
medicines of equivalent effect that are safer for use in the secure setting, a plan will be 
agreed to provide assisted withdrawal from a particular medicine, with a 
multidisciplinary approach to supporting those patients with complex problems or with 
concurrent substance misuse issues. There is no place for abrupt cessation of 
medicines due to the risk of withdrawals and attendant distress. 
 
RCGP Safer Prescribing in Prisons 2nd edition (RCGP 2019) recommends judicious 
prescribing in secure environments that take account of the risk of a particular 
prescribed medicine to the patient and to the wider population. The use of a formulary 
that reflects guidance such as the Prison Pain Formulary, Opioids Aware and Safer 
Prescribing in Prisons is recommended. There are clear directives on the storage and 
handling of prescribed Controlled Drugs in Secure Environments and most medicines 
liable to dependence and withdrawal will be administered under supervision to minimise 
the risk caused by diversion and misuse. In lower security environments, some 
medicines may be given in possession, with compliance checks being carried out to 
confirm that they are being taken correctly. 
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References and further reading 
 
This content was adapted from RCGP 2019 Safer Prescribing in Prisons: Guidance for 





The Prescribed Medicines Review does not cover drug misuse, except insofar as it 
involves prescribed medicines and is the result of prescribing. However, issues of 
prescribing, dependence and misuse are complex, overlapping and important. Some 
people may become dependent on prescribed medicines and then, when they are no 
longer prescribed, seek them from other sources, including online. Others may misuse 
the medicines they are prescribed: taking too much, seeking early repeat prescriptions, 
etc. Other people may misuse, and become dependent on, illicit drugs and then seek to 
replace them with prescribed medicines. Some may persuade a doctor to prescribe 
them. Others may obtain prescription medicines through routes other than prescription: 
stolen or diverted from pharmacies or warehouses, sold or given by those to whom they 
were prescribed, bought off the internet, etc. 
 
This is a complex spectrum onto which different people’s histories fall, and may then 
move. The focus of the Prescribed Medicines Review is on one end of the spectrum, 
where patients are prescribed a medicine and then inadvertently become dependent or 
suffer withdrawal. But attention and care are needed across the spectrum. 
 
In particular, people with a current or past history of substance misuse or in recovery 
from dependence on drugs need clinical understanding and expertise to treat their 
legitimate need for medicines that can cause dependence and withdrawal, especially 
opioids when they are in acute pain or at the end of life. This issue is covered in more 
detail in the 2017 Clinical Guidelines, British Pain Society guidance, and the online 
Opioids Aware resource. 
 
Dependence on and misuse of opioids, benzodiazepines, pregabalin and others can be 
driven by the availability of medicines excessively prescribed and consequently 
diverted. These are issues receiving attention from the Medicines and Healthcare 
products Regulatory Agency (MHRA), Care Quality Commission (CQC) and General 
Pharmaceutical Council (GPhC), among others. 
 
ATOMIC (Addiction TO Medication: Improving Care) is a Health Foundation-funded 
project being run by Central and North West London NHS Foundation Trust to improve 
patient care by increasing clinicians’ knowledge and competence in identifying, 
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assessing and managing the misuse of medication by young people 
https://clubdrugclinic.cnwl.nhs.uk/need-help/addiction-online-medicine-service/ 
 
References and further reading 
 








Pain and substance misuse: improving the patient experience, BPS 2007 
www.britishpainsociety.org/static/uploads/resources/misuse_0307_v13_FINAL.pdf 
 
Opioids Aware www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware 
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Appendix C. Search strategy for initial literature scoping search 
(Search strategies for the rapid evidence assessment are in the separate REA reports) 
 
Database(s): Embase 1996 to 2018 Week 12  
1 exp *inappropriate prescribing/ 
2 (prescri* adj1 (drug* or medic*)).tw. 
3 1 or 2 
4 (Opioid* or Buprenorphine or Codeine or Dextromoramide or Diamorphine or 
Dihydrocodeine or Dipipanone or Fentanyl or Hydromorphone or Meptazinol or 
Methadone or Morphine or Oxycodone or Pentazocine or Pethidine or 
Tapentadol or Tramadol).tw. 
5 (Benzodiazepine* or Z-drug* or Zaleplon or Zopiclone or Zolpidem or Flurazepam 
or Loprazolam or Nitrazepam or Temazepam or Diazepam or Chlordiazepoxide 
or Lorazepam or Oxazepam).tw. 
6 (Gabapentinoid* or Pregabalin or Gabapentin).tw. 
7 (Antidepressant* or Tricyclics or Amitriptyline or Amoxapine or Clomipramine or 
Dosulepin or Doxepin or Imipramine or Lofepramine or Maprotiline or Mianserin 
or Nortriptyline or Protriptyline or Trazodone or Trimipramine).tw. 
8 (MAOI* or Isocarboxazid or Moclobemide or Phenelzine or Tranylcypromine).tw. 
9 (SSRI* or Citalopram or Escitalopram or Fluoxetine or Fluvoxamine or Paroxetine 
or Sertraline).tw. 
10 (Agomelatine or Duloxetine or Flupentixol or Mirtazapine or Nefazodone or 
Oxitriptan or Reboxetine or Tryptophan or Venlafaxine or Vortioxetine).tw. 
11 ((non-cancer or "non cancer") adj (drug* or medic*)).tw. 
12 or/4-11 
13 exp *addiction/ 
14 (abus* or addict* or dependen* or withdrawal or "discontinuation syndrome").tw. 
15 13 or 14 
16 (risk* or prone or suseptib* or vulnerab* or reason).tw. 
17 ((community or social) adj (intervention* or prescribing or referral* or support or 
program* or treatment)).tw. 
18 (behavio?r* adj (cognitive or change)).tw. 
19 (psychosocial or biopsychosocial or bio-psychosocial).tw. 
20 17 or 18 or 19 
21 3 and 15 and 16 
22 3 and 15 and 20 
23 12 and 15 and 16 
24 12 and 15 and 20 
25 limit 21 to (human and yr="2007 -Current") 
26 limit 22 to (human and yr="2007 -Current") 
27 limit 23 to (human and yr="2007 -Current") 
28 limit 24 to (human and yr="2007 -Current")  
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Appendix D. Statistical analysis plan for the NHSBSA prescription data 
Here, the aims, administrative information, definitions and methods used for the 
analysis of data gathered for PHE’s prescribed medicines review (PMR) are described. 
The goal of the review’s statistical analysis plan (SAP) is to ensure that the approach to 
answering a primary research question: “What is the overall volume and duration of 
prescribing over time and among sub-populations and by socio-demographic factors?”, 
is approached and implemented in a pre-specified, transparent way to enable scrutiny, 
interpretation and reproducibility. 
 
The analysis of any data set will always rest on assumptions and often pragmatic 
decisions. This SAP is intended to give the reader a non-technical – but sufficient – 
description to facilitate interpretation of the analyses, and their strengths and limitations. 
Further descriptions of quality assurance processes and results and technical aspects 
of data-linkage and analysis will be attached to future publications. 
 
This document was prepared by Martin White, John Marsden, Jon Knight and Steve 
Taylor from PHE’s Alcohol, Drugs, Tobacco & Justice Division and was informed by 
discussion with members of the project team and the ERG. Following independent 
review, and further interval quality assurance, the SAP may be revised. 
 
The SAP has 6 sections: 
 
1. Overview on data sources and exclusions 
2. Definitions 
3. Social-demographic and local administrative data 
4. Analysis  
5. Limitations  
6. Planned sensitivity analyses 
 
An additional section describes other data or analysis included, and a separate 
appendix (A) shows the list of medicines included. 
 
1. Overview on data sources and exclusions 
The primary data source will be electronic and paper prescriptions data on all NHS 
prescriptions dispensed by medical practitioners (not dentists) to patients registered in 
the community in England by NHSBSA (April 2015 to March 2018). These data are 
collected to facilitate reimbursement to retail pharmacies and have obvious limitations 
for epidemiological research given the short-term nature of the data and the specific 
information collected within this dataset. 
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Since April 2015 NHSBSA have collected NHS Number - which is necessary to link 
prescriptions for the same person. Electronic prescriptions account for the majority of 
the data; for paper forms, only the month of submission to NHSBSA is known (herein, 
‘reimbursement month’) and this is the base unit of time at which the data will be 
analysed. 
 
All prescriptions data otherwise relevant will be discounted if the NHS Number is not 
recorded (a small percentage of cases). Given the goal of the review, we will remove 
data on opioid medications prescribed to patients with cancer. This will be achieved 
through data linkage with the National Cancer Registration Dataset (held by the 
National Cancer Registration and Analysis Service in PHE) so that all persons with 
cancer on that register are not included in the analysis. It is acknowledged that some 
opioid prescribing for terminal pain and also prescribing of gabapentin and pregabalin 
for epilepsy cannot be identified and removed. 
 
Data on opioid prescribing to patients with opioid use disorder will also be removed via 
either the use of BNF codes specifying prescription for opioid substitution treatment or 
identification of smaller quantities (instalments) at specified intervals on the FP-10 MDA 
form.  
 
All exclusions apply to specific prescriptions and do not exclude other prescriptions in 
scope (for example, data concerning a methadone prescription for opioid use disorder is 
not included, but if the same patient is also prescribed a non-opioid medication within 
scope, this data is included). 
 
2. Definitions  
Reimbursement month: This is not necessarily the month the prescription was issued 
to the patient and it is not a valid indicator of whether the medication was actually taken 
by the patient. It is judged reasonable to assume that retail pharmacies implement 
procedures to submit data for payment close to the date of prescription in most 
instances.  
 
Duration of prescribing: For the analysis, ‘duration of prescribing’ will be defined as 
the number of consecutive months that at least one prescription is identified relating to 
the same patient for medication within the same medicine class. For the main indicator, 
a person could have a gap (or multiple gaps) of one month within a period of continuous 
prescribing, without this ending the period of prescribing. This allows, for example, a 
person with a prescription reported every other month to be counted as receiving 
prescriptions continuously throughout. Analyses will also be done out using  2 other 
rules: (1) allowing no gap (i.e. a prescription in each month); (2) allowing gaps of up to  
2 months. 
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Duration will be reported either prospectively or retrospectively. The prospective method 
considers all those starting a new period of continuous prescribing in a specific month 
and reports the breakdown of how long they ultimately receive the prescription. The 
retrospective method considers all those currently in receipt of a prescription at any time 
and reports how long they have been in receipt of continuous prescribing up to that 
point. 
 
Our methodology for defining duration does not identify occasions where there are 
prescriptions reported in the same month for multiple drugs for the same individual, 
either within the same or different medicine classes. Our aim is to relate the data to the 
recommended maximum duration for each medicine class, where this is available. NICE 
have produced a mapping to support this. However, because reimbursement month is 
available but not the exact prescribing date, there will be instances of uncertainty as to 
whether a person has been prescribed to for longer or shorter than the recommended 
maximum duration. 
 
The definition of duration used cannot identify exactly how long the patient has been 
treated by a medication. There are  2 consequences here: (1) there will be cases in 
which a person appears in consecutive months and will, therefore, be taken as being 
prescribed to continuously – but there may have been time when there was no 
prescription; and (2) there will be cases where an individual has been prescribed to 
continuously, but a gap appears in the reported data because (among several possible 
reasons) the prescription data is submitted late for payment. The assumption however 
is that in usual circumstances the pattern of prescriptions observed within the dataset 
reflects the frequency with which the patient received prescriptions and accordingly 
inferences can be made to estimate the duration of continuous prescribing. 
 
Co-prescribing: Co-prescribing is defined as the report to NHSBSA for payment of 
from  2 or more different medicine classes within the same month (i.e. multiple 
prescriptions within the same class are not considered to be co-prescribing). Specific 
co-prescribing combinations are reported. 
 
3. Social-demographic and local administrative data 
Counts of prescribing activity will be compared to published English general population 
data broken down by age (<18 years, 18-24 years, then in 5-year bands to 95+, as used 
in tabulations of each GP practice population) and sex, in order to estimate differences 
in prescribing patterns. These data will be used to calculate standardised rates by 
Clinical Commissioning Group (CCG) and crude rates at GP practice level (but not 
identifying any CCG or practice by name within the report). 
 
For national rates, including by age group and sex, English resident populations will be 
used for prescribing rates to address known double-counting across GP registers. For 
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this analysis, the oldest age group is grouped at 90+ in accordance with the cut-off used 
in mid-year population estimates. 
 
A methodology used within PHE’s GP practice profiles will be used to map GP practice 
localities to a deprivation score using the Indices of Multiple Deprivation (IMD for the 
April 2016 population). Practices will then be grouped by the quintile of their deprivation 
score and breakdowns by deprivation are reported for each quintile, aggregated from 
practice data. 
 
Confidence intervals will be applied using the Wilson Score method in accordance with 
the methods advised by the Association of Public Health Observatories. 
 
4. Analysis  
For each class and for the 3-year period, the overall volume, prescribing duration 
and co-prescribing will be reported over the 3 years by age, sex and deprivation 
quintile. Denominators for overall proportions at GP practice and CCG level will be 
calculated by summing published monthly data on the number of patients registered at 
each GP practice and then each CCG. 
 
Reporting at national level will be based on the English resident mid-year population 
estimates as described above. The nature of change in prescribing rates and 
prescription duration over time will be shown. Co-prescribing of  2 or more different 
medicine classes will be summarised by age group, sex, CCG and deprivation, and all 
the combinations of co-prescription observed (totals only). 
 
5. Limitations  
Prescribing duration: The retrospective and prospective approaches of addressing the 
question of duration will need to be interpreted very carefully and have inherent 
limitations, given the left and right truncation of this data and its relatively short period. 
 
The retrospective analysis is anchored on the population in receipt of prescriptions at 
any given time and their distribution by duration as at that time. As such, while the 
analysis will show ‘X% of people in receipt of a prescription at [a given month] have 
been receiving the prescription continuously for Y months’, it will not be possible to infer 
that there is a general X% likelihood of a person receiving a prescription continuously 
for at least that time. Statements referring to the extent of people prescribed a drug for 
at least X months will therefore only refer to the trend from at least X months into this 
period. For example, it will not be possible to estimate proportion of people who were in 
receipt of a prescription for at least 12 months consecutively until the twelfth month 
(March 2016). 
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For many patients who have a retrospective continuous prescribing period identified 
back to the beginning of the period of study (April 2015) the prescribing will have been 
longstanding by this point. As such, the estimate for this group can only ever reflect the 
minimum duration for that group. For those prescribed to since March 2018 it will be 
stated they have been prescribed to for at least 36 months. Furthermore, there may be 
examples where a person is tracked back by our method to May 2015, but it will not be 
possible to view March 2015 data to establish if the gap in April 2015 was for a single 
month only. A pragmatic view will therefore be taken that a person who is identified from 
May 2015 to March 2018 will be considered to have had a continuous prescription 
through April 2015 (if this data was available), and that they received a prescription for 
the whole period. 
 
The prospective analysis will include people who are receiving a prescription before 
April 2015, so it will not be possible to use the earliest months (particularly April 2015) 
as many patients will not truly be starting a prescription in that month. June 2015 is 
used as the baseline month to address this issue. Statements referring to the extent of 
people prescribed a drug for at least X months will therefore only refer to the trend from 
at least X months from the end of time series. For example, it will not be possible to 
estimate what proportion of people at the reimbursement month were in receipt of a 
prescription for at least 12 months consecutively after April 2017. 
 
For the co-prescribing analysis there will be occasions within the data where 
prescriptions from different medicine classes are submitted to NHSBSA for an individual 
within the same month but in fact the prescriptions were consecutive within that month, 
potentially without overlap. Options for defining co-prescribing in a more restricted way 
(such as prescriptions on the same form or the same date) were considered but an 
exact prescription date will not be available in all cases and, although prescriptions 
listed on the same form can be identified, drugs being co-prescribed may not appear on 
one form (perhaps because there was limited space to record multiple prescriptions on 
the same form). It is anticipated that adopting this definition of co-prescribing will lead to 
overstatement of true rates of co-prescribing. It is also possible that a person may have 
had a relevant combination of medicines prescribed in the same month but the 
prescriptions were, for unknown reasons, submitted in different months of prescriptions 
data. Conversely, they may not have had the relevant combination of medicines 
prescribed within the same month, but they happened to be submitted to NHSBSA for 
payment within the same month. 
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6. Planned sensitivity analyses 
The SAP includes the following planned sensitivity analyses, and there may be other 
analyses specified following report review and internal quality assurance. 
 
Missing NHS Numbers: An analysis will be done of the extent of missing NHS 
Numbers nationally on prescription forms in a one-year period, by the medicine class, 
age and sex. This will determine potential bias created by excluding those without NHS 
Numbers. 
 
FP-10 MDA forms: An analysis will be done of FP10-MDA forms over a one-year 
period, by drug name (other than those identified by the BNF code as being for opioid 
substitution treatment). This will identify which substances are being prescribed in 
instalments and have been excluded.  
 
Co-prescribing in consecutive months: A variation of the analysis of co-prescribing 
will be carried out, which only counts co-prescribing combinations which are repeated in 
either the preceding or following month. This will provide an estimate of the co-
prescribing rate by seeking to remove co-prescribing combinations which appear in a 
single month in isolation and which therefore may reflect a transition between medicine 
classes. 
 
Complementary data sources used 
Several other data sources are used to complement the main analysis, either covering 
prescribing other than in the community, or to give longer term trends than the main 
analysis allows: 
 
Routinely published Prescription Cost Analysis (PCA) data from NHSBSA is used to 
show trends in community prescribing back to 2008, counting numbers of prescriptions. 
This is the same data as used in the main analysis, but data at individual level is not 
available. 
 
Data collected from other settings (hospitals, care homes and private prescriptions) will 
be provided by the private company IQVIA. This covers a slightly different period to our 
main analysis (November 2016 to October 2018) and contains counts of prescriptions or 
rather than data at individual level. It should be noted that there are considerable 
differences in the volume of prescriptions in each setting, with community data by far 
the largest and private prescribing the smallest, and numbers reported from smaller 
settings will have greater volatility. To reduce the impact of noise in the data, the data 
will be grouped into 3-month periods. 
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Analyses carried out by the Public Health Research Consortium in tandem with our 
review will also be reported. These analyses use the Clinical Practice Research 
Datalink (a representative sample of GP practices) and explore patterns of prescribing 
for the same medicines for the period 2000-2015. This includes examination of 
continuous prescribing using a different method to that used in the review’s report. Their 
work will update and expand earlier work reported in Prescribing Patterns in 
Dependence Forming Medicines (2017). 
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Appendix E. Call for papers invitation 
Review of the evidence on dependence, short-term discontinuation and longer-term 
withdrawal symptoms associated with prescribed medicines 
Call for evidence 
 
Please forward this letter to any relevant organisations or individuals with expertise or 






Public Health England has commissioned the National Guideline Centre (NGC) to 
produce an evidence review of the literature on dependence, discontinuation and 
withdrawal from prescribed medicines, and their prevention and treatment.  
 
We are inviting stakeholders to submit research data or reports (see details below for 
the formats that will be accepted) on 2 key areas to inform the review:  
 
• collations of patients’ experiences of the harms caused by prescribed medicines and 
ability to access and engage in treatment specifically relating to dependence, short 
term discontinuation or longer term withdrawal symptoms from the following 
prescribed medicines: opioids for chronic pain (excluding end of life /palliative 
care/cancer pain), benzodiazepines, z-drugs, gabapentin and pregabalin (excluding 
epilepsy treatment), and antidepressants. (In England only) 
 
• effectiveness and cost effectiveness of current examples of health/social service 
delivery models that prevent or treat dependence and the short term discontinuation 
or longer term withdrawal symptoms (opioids for chronic pain (excluding end of life 
/palliative care/cancer pain), benzodiazepines, z-drugs, gabapentin and pregabalin 
(excluding epilepsy treatment), and antidepressants). (In England, as well as health 
service delivery models in other countries that might inform provision in England) 
 
We would like: 
 
• information published between 2008 and 2018 
• unpublished information related to research carried out between 2008 and 2018, 
including any ongoing research 
• reports which summarise/collate patient experiences e.g. organisational reports or 
internal evaluations of projects or services (the views, experiences and opinions of 
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individual professionals, researchers, commentators or patients will not be able to be 
included, however) 
 
We are especially interested in the following outcomes for part b: 
 
• reduction/cessation in prescribed drug use 
• successful withdrawal 
• cost effectiveness 
• use of healthcare resources 
• health-related quality of life  
• patient/staff satisfaction 
• social outcomes e.g. employment, relationships, parenting 




For published information, send only the details (to include author/s, title, date, journal 
or publication details, including volume and issue number, and page numbers). Do not 
send a pdf/Word document or paper copy. 
 
For unpublished information, send: 
 
• a link to any relevant trials registered with the Cochrane Central Register of 
Controlled Trials, or with the US National Institutes of Health trials registry 
• paper or electronic copies of other relevant unpublished information 
 
Highlight any confidential sections (unpublished research or commercially sensitive 
information) in unpublished information. 
 
Email prescribedmed@rcplondon.ac.uk these forms with any relevant information by 
midnight on Tuesday 23 October 2018. 
 
We look forward to receiving information and thank you in advance for your help. 
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Appendix F. Papers describing relevant services – with no evaluation 
In addition to the included studies, further submissions provided descriptions of 
programmes of interest which were in the public domain, but no evaluation or outcomes 
were available at time of submission that could be analysed within the report of 
effectiveness of the service. These are excluded from the analysis but are listed and 
briefly described below as examples of programmes, services or research available and 
in progress: 
 
British Medical Association (2017) Chronic pain: supporting safer prescribing of 
analgesics. London: British Medical Association   
A briefing paper highlighting some of the key issues surrounding the use of analgesics 
in the management of patients with chronic pain, setting out a range of 
recommendations for governments, policy makers and healthcare professionals, with 
the aim of supporting the safer prescribing of these medicines. While it provides an 
introduction to the current state of the evidence in this area, it is not intended to provide 
a systematic review of the evidence or act as a clinical guide. A comprehensive 
resource to support the clinical use of opioids – Opioids Aware – has also recently been 
developed and is discussed within this report. 
 
The Faculty of Pain Medicine’s resource ‘Opioids aware’ 
www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware 
 
A resource written and collated by healthcare professionals with the support of 
stakeholder policy groups to provide information to support a safe and effective 
prescribing decision for opioids. This is an online resource which covers aspects 
including: 
 
• best professional practice 
• understanding pain and medicines for pain 
• clinical use of opioids 
• a structured approach to opioid prescribing 
• opioids and addiction 
• information for patients 
 
Centre for Effective Practice Opioid Tapering Template 
https://thewellhealth.ca/opioidtaperingtool 
 
A tool developed in Ontario, Canada designed to assist family physicians and primary 
care nurse practitioners on developing tapering plans with their patients and adjusting 
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those plans as their patients’ needs change due to pain, function and withdrawal 
symptoms. It is a template that can be freely downloaded from the website. The tool is 
divided into 5 sections to guide providers through the opioid tapering process which are: 
 
• important considerations for opioid tapering 
• how to taper, reduce or discontinue 
• withdrawal symptoms & management 
• tapering plan 
• follow-up tapering visits 
 
I-WOTCH: Improving the Wellbeing of People with Opioid Treated Chronic Pain 
https://warwick.ac.uk/fac/sci/med/research/ctu/trials/iwotch/health/ 
 
An ongoing randomised controlled trial with the Warwick Clinical Trials Unit to test the 
effectiveness and cost effectiveness of a multicomponent self-management intervention 
targeting withdrawal of strong opioids in comparison to best usual care (that is, the 
control intervention) for people living with persistent pain. 
 
NHS Gloucestershire Living Well with Pain Programme 
www.gloucestershireccg.nhs.uk/your-health/health-topic/pain/ 
 
The aim of the programme is "Making Gloucestershire the best place to live with 
persistent pain and to protect patients from the harms of pain treatments." The 
programme addresses challenges in managing pain generally and prescribing 
specifically. ‘Upstream’ and ‘downstream’ approaches are used. Upstream interventions 
promote a shared understanding of the complexity of persistent pain. Downstream 
initiatives focus on support and management for patients who remain on high dose 
opioids, often in combination with other psychoactive drugs, many of whom have failed 
to make progress with specialist support. Other elements include development of a joint 
formulary and promotion of the key concept of “first do no harm:” Offering 
multidisciplinary assessment for complex patients and follow-up of these patients with 
their GP. Running training sessions for primary care staff in the community and 
masterclasses for healthcare professionals, exploring conversations in pain 
management and using themes from transactional analysis to recognise prescribers’ 
own behaviours and feelings in consultations that often lead to poor prescribing 
decisions. Implementing a risk mitigation programme to ensure that all patients taking 
high dose opioids and those taking multiple opioids or opioids in combination with other 
medicines, particularly gabapentinoids, antidepressants and benzodiazepines are 
identified and reviewed in primary care to optimise their prescriptions and reduce 
exposure to harm. 
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The pilot project aims to address the misuse of prescribed medications. It is seeking to 
establish how to work more effectively alongside GPs in primary care settings. The pilot 
has been commissioned to be delivered by Developing Health & Independence (DHI), in 
conjunction with Battle Against Tranquillisers (BAT) between July 2016 and June 2018. 
The effectiveness of the Pilot Project will be evaluated by NIHR CLAHRC West. 
(Evaluation not available at time of development of this rapid evidence assessment). 
 
REDUCE Programme Work Stream 4: REviewing long term anti-Depressant Use by 
Careful monitoring in Everyday practice. Randomised controlled trial 
www.isrctn.com/ISRCTN15036829  
 
The REDUCE (REviewing long term antiDepressant Use by Careful monitoring in 
Everyday practice) study aims to identify safe, effective, and cost-effective ways of 
helping patients taking long-term antidepressants taper off and stop treatment, when 
appropriate. This study aims to determine the feasibility of a randomised controlled trial 
of online (Internet) interventions to support practitioners and guide patients on coming 
off antidepressants. The aim is to assess the acceptability of the Internet interventions, 
recruitment of practitioners and patients, and acceptability of planned outcome 
measures. 
 
